Protocol for studying macrophage lipid crosstalk with murine tumor cells Authors: Daan J Kloosterman, Martina Farber, Menno Boon, Johanna Erbani, Leila Akkari Published: 2024 ABSTRACT SummaryLipid accumulation has recently emerged as a key feature underlying the pro-tumorigenic role of macrophages. Here, we present a workflow to study macrophage lipid crosstalk with tumor cells. We describe steps for the identification, purification, and multi-omics characterization of lipid-laden macrophages (LLMs) from murine tumors and outline protocols to assess the functional significance of LLMs in cancer malignancy. This approach has the potential to uncover the source of lipids that drives LLM formation and its pro-tumorigenic potential in multiple cancer types.For complete details on the use and execution of this protocol, please refer to Kloosterman, Erbani, et al.1Subject areas: bioinformatics, sequence analysis, cell biology, single cell, flow cytometry, cancer, genomics, RNA-seq, immunology, microbiology Before you begin Lipid metabolism underlies the pro-tumorigenic phenotype of tumor-associated macrophages in multiple cancers.2,3,4 The protocol below was designed to identify and purify lipid-laden macrophages for multi-omics characterization in a brain tumor, glioblastoma mouse model, as described previously by Kloosterman, Erbani and colleagues.1 This workflow led to the discovery that macrophages acquire a lipid-laden phenotype through phagocytosis of lipid-rich myelin debris. These lipid-laden macrophages (LLMs) efflux myelin-derived lipids to tumor cells to fuel their proliferation. The brain tumor tissue used in these protocols was obtained from a genetically-engineered mouse model of glioblastoma employing the RCAS/t-va technology, as previously described.5 Briefly, glioblastoma was induced by intracranially injecting DF-1 cells expressing an RCAS (Replication-Competent ASLV long terminal repeat (LTR) with a Splice Acceptor) vector encoding PDGF-B HA into 5- to 7-week-old Nestin-TV-a;Ink4a/Arf−/− mice (BL/6 background). Tumor progression was assessed by weekly MRI scans where tumor volumes were measured as previously described.6 The mice were euthanized and brains harvested for use in the below protocols once the tumor reached a volume of 90–120 mm3. While this protocol was developed and used in a glioblastoma model, we also show an example of collecting and interpreting data from a hepatocellular carcinoma (HCC) mouse model,7,8 indicating that this workflow can be applied to the study of lipid-laden macrophages in multiple murine cancer models. Institutional permissions This protocol requires the use of animal samples. All animal experiments should be performed in accordance with relevant governmental and institutional guidelines. Tumor tissue was obtained from genetically engineered mouse models of glioblastoma as described previously.6,9,10,11 Mice used for the generation of bone marrow derived macrophages were aged between 8-13 weeks. All mouse procedures were approved by the animal ethics committee of the Netherlands Cancer Institute and performed in accordance with institutional, national and European guidelines for animal care and use. Key resources table REAGENT or RESOURCESOURCEIDENTIFIERAntibodiesCD11b BV650 (clone M1/70), dilution 1:400BD BiosciencesCat# 563402CD11b BV786 (clone M1/70), dilution 1:1,200BioLegendCat# 101243CD11c PE-Cy5.5 (clone N418), dilution 1:200Life TechnologiesCat# 35-0114-82CD31 BV421 (clone 390), dilution 1:400BioLegendCat# 102424CD36 APC (clone HM36), dilution 1:150BioLegendCat# 102612CD45 AF700 (clone 30-F11), dilution 1:200BioLegendCat# 103128CD49d PE-Cy7 (clone R1-2), dilution 1:150BioLegendCat# 103618Fc blocking reagent (aCD16/CD32), dilution 1:400BD BiosciencesCat# 553142Ki67 BV785 (clone B56), dilution 1:200BD BiosciencesCat# 563756Ly6C BV605 (clone HK1.4 ), dilution 1:400BioLegendCat# 128036Ly6G BV711 (clone 1A8), dilution 1:200BioLegendCat# 127643MHC II PerCP-eFluor710 (clone M5/114.15.2), dilution 1:1,000InvitrogenCat# 46–5321-82Chemicals, peptides, and recombinant proteinsPBSGibcoCat# 18912014DMEMGibcoCat# 61965059RPMI-1640GibcoCat# 11875093Penicillin-StreptomycinRocheCat# 110774440001Trypsin-EDTAGibcoCat# 15400-054DMSOSigma-AldrichCat# 276855Paraformaldehyde, 16%Thermo Fisher ScientificCat# 043368.9MTritonSigma-AldrichCat# 9002-93-1SaponinSigma-AldrichCat# S4521HBSSGibcoCat# 24020-133Poly-D-LysineThermo Fisher ScientificCat# A3890401RLT bufferQIAGENCat# 79216BSARocheCat# 03116964001FCSCapricorn ScientificCat#FBS-12ALipid-depleted FCSBiowestCat# S181L-500CSF-1R&DCat# 4160MLLXR antagonist (GSK2033)MedChemExpressCat# HY-108688Abca1 inhibitor (Valspodar)Sigma-AldrichCat# SML0572Alkyne cholesterolClick Chemistry toolsCat# 1409-5BD brilliant stain bufferBD BiosciencesCat# 566349BODIPY 493/503Thermo Fisher ScientificCat# D3922Zombie NIRBioLegendCat# 423105Critical commercial assaysBrain Tumor Dissociation KitMiltenyiCat# 130-095-942Fixation/Permeabilization ConcentrateThermo Fisher ScientificCat# 00-5123-43Fixation/Permeabilization DiluentThermo Fisher ScientificCat# 00-5223-56Permeabilization buffereBioscienceCat# 00-8333-56BD brilliant stain bufferBD BiosciencesCat# 566349Click-iT EdU Alexa Fluor 647 Flow Cytometry Assay KitThermo Fisher ScientificCat# C10419Myelin Removal Beads IIMiltenyiCat# 130-096-433CD11b MicrobeadsMiltenyiCat# 130-093-634UltraComp eBeads Compensation BeadseBioscienceCat# 01-2222-42Propidium iodideThermo Fisher ScientificCat# P3566RNase AThermo Fisher ScientificCat# EN0531Deposited dataGlioblastoma reference dataKloosterman et al.1GEO: GSE266149HCC reference dataRamirez et al.7GEO: GSE216717Reference datasetThis paperhttps://doi.org/10.5281/zenodo.13811090Experimental models: Cell linesMouse: primary PDG-Ink4a glioblastomaKloosterman et al.1N/ADF1-PDGFB-HA, DF1 chicken fibroblasts (ATCC) with RCAS viral vector expressing PDGFB-HADr. Tatsuya Ozawa and Dr. Eric HollandN/AExperimental models: Organisms/strainsMus musculus, C57BL/6J, 8–13 weeks, male/femaleThe Jackson LaboratoryRRID:IMSR_JAX:000664Mus musculus, Gt(ROSA)26Sortm4(ACTB-tdTomato,-EGFP)Luo/J (C57BL/6J background), 8–13 weeks, male/femaleThe Jackson LaboratoryRRID:IMSR_JAX:007576Mus musculus, Nestin-Tv-a;Ink4a/Arf−/− (C57BL/6J background), 6–12 weeks, male/femaleHolland et al.12N/AMus musculus, HDTVi- NrasG12D/PtenKO (C57BL/6J background), 6–12 weeks, male/femaleRamirez et al.7N/ASoftware and algorithmsFlowJo, version 10.8.0BD Bioscienceshttps://www.flowjo.com/GraphPad Prism, version 10.0.3 (217)GraphPad Softwarehttps://www.graphpad.com/FlowJo, version 10.8.0BD Bioscienceshttps://www.flowjo.com/R environment, version 4.3.2The R Foundationhttps://www.r-project.orgRStudio, version 2023.09.1 + 494RStudiohttps://www.posit.co/OthergentleMACS Octo DissociatorMiltenyiCat# 130-095-037gentleMACS C-tubesMiltenyiCat# 130-096-334LS columnsMiltenyiCat# 130-042-401BD LSRFortessa, flow cytometerBD BiosciencesN/AFACSAria Fusion, flow cytometer & cell sorterBD BiosciencesN/ATeflon bag 30 mLOriGenCat# PL30Teflon bag 7 mLOriGenCat# PL0770 μm Cell strainerFalconCat# 35235040 μm Cell strainerFalconCat# 35234020 μm Nylon net filters, 47 mmMerckCat# NY2004700Amicon Ultra-15 centrifugal filter unitMilliporeCat# UFC901096CELLSTAR flask, TC, PS, 50 mL, 25 cm2 (T25)Greiner Bio-OneCat# 690160CELLSTAR flask, TC, PS, 250 mL, 75 cm2 (T75)Greiner Bio-OneCat# 658170CELLSTAR flask, TC, PS, 550 mL, 175 cm2Greiner Bio-OneCat# 660160CELLSTAR plate, 6w, TC, PS, 2–5 mL/wGreiner Bio-OneCat# 657165CELLSTAR plate, 12w, TC, PS, 2–4 mL/wGreiner Bio-OneCat# 662160CELLSTAR 96-Well cell culture plate U bottomGreiner Bio-OneCat# 650180Sterile disposable scalpelsSwann-MortonCat# 0506 Materials and equipment Brain tumor dissociation mixture (prepare fresh)ReagentFinal concentrationAmount for one tumorDMEMN/A2.4 mLEnzyme DN/A100 μLEnzyme RN/A50 μLEnzyme AN/A12.5 μL Brain tumor dissociation mixture (prepare fresh) Flow cytometry staining buffer (FB) (store at 4°C for up to 3 months)ReagentFinal concentrationAmount for 500 mLPBSN/A490 mLFetal Calf Serum (FCS)2%10 mL Flow cytometry staining buffer (FB) (store at 4°C for up to 3 months) Myelin removal bead solution (prepare fresh)ReagentFinal concentrationAmount for one tumorFBN/A1.9 mLMyelin removal beads1:20100 μL Myelin removal bead solution (prepare fresh) Red blood cell lysis buffer (store at 4°C for up to 3 months)ReagentFinal concentrationAmount for 1 LNH4Cl157 mM8,4 gNaHCO314 mM1,2 g0,5M EDTA0,1 mM200 μLdH2ON/A1 L Red blood cell lysis buffer (store at 4°C for up to 3 months) Blocking buffer (BB) (prepare fresh)ReagentFinal concentrationAmount for 100 μLBD brilliant stain bufferN/A99.75 μLFc blocking reagent (aCD16/CD32)1:4000.25 μL Blocking buffer (BB) (prepare fresh) Fixation solution (prepare fresh)ReagentFinal concentrationAmount for 2 mLFixation diluent3:41.5 mLFixation concentrate1:40.5 mL Fixation solution (prepare fresh) Permeabilization buffer (prepare fresh)ReagentFinal concentrationAmount for 10 mLDeionized waterN/A9 mLPermeabilization buffer1:101 mL Permeabilization buffer (prepare fresh) Antibody mix 1 (prepare fresh)ReagentDilutionFluorophoreAmount for 100 μLBrilliant stain bufferN/AN/A95.82 μLCD451:200AF7000.5 μLCD11b1:400BV6500.25 μLLy6G1:150BV7110.66 μLLy6C1:400BV6050.25 μLCD49d1:150PE-Cy70.66 μLCD311:1000BV4210.1 μLCD11c1:200PE-Cy5.50.5 μLMHC II1:1000PerCP-eFluor7100.1 μLPD-L11:200PE0.5 μLCD361:150APC0.66 μL Antibody mix 1 (prepare fresh) Antibody mix 2 (prepare fresh)ReagentFinal concentrationFluorophoreAmount for 100 μLBrilliant stain bufferN/AN/A99.5 μLCD451:200AF7000.5 μL Antibody mix 2 (prepare fresh) Antibody mix 3 (prepare fresh)ReagentFinal concentrationFluorophoreAmount for 100 μLBrilliant stain bufferN/AN/A97.68 μLCD451:200AF7000.5 μLCD11b1:400BV6500.25 μLLy6G1:150BV7110.66 μLLy6C1:400BV6050.25 μLCD49d1:150PE-Cy70.66 μL Antibody mix 3 (prepare fresh) Antibody mix 4 (prepare fresh)ReagentFinal concentrationFluorophoreAmount for 100 μLPermeabilization bufferN/AN/A99.5 μLKi671:200BV7850.5 μL Antibody mix 4 (prepare fresh) Antibody mix 5 (prepare fresh)ReagentFinal concentrationFluorophoreAmount for 100 μLFBN/AN/A99,42 μLCD11b1:1200BV7850.08 μLCD451:200AF7000.5 μL Antibody mix 5 (prepare fresh) Zombie NIR live/dead staining solution (prepare fresh)ReagentFinal concentrationAmount for 1 mLPBSN/A999 μLZombie Near InfraRed (NIR)1:10001 μL Zombie NIR live/dead staining solution (prepare fresh) BODIPY staining solution (prepare fresh)ReagentFinal concentrationAmount for 1 mLFBN/A999.99 μLBODIPY 493/5031:1000000.01 μL BODIPY staining solution (prepare fresh) Maintenance media (store at 4°C for up to 3 months, sterile)ReagentFinal concentrationAmount for 500 mLDMEMN/A440 mLFetal Calf Serum (FCS)10%50 mLPen/Strep2%10 mL Maintenance media (store at 4°C for up to 3 months, sterile) Note: Amount needed for T25 flask is 4 mL, for T75 is 12 mL and T175 is 25 mL. Low-serum media (store at 4°C for up to 3 months, sterile)ReagentFinal concentrationAmount for 500 mLDMEMN/A480 mLFetal Calf Serum (FCS)2%10 mLPen/Strep2%10 mL Low-serum media (store at 4°C for up to 3 months, sterile) Lipid-free media (store at 4°C for up to 3 months, sterile)ReagentFinal concentrationAmount for 500 mLDMEMN/A480 mLLipid-free FCS2%10 mLPen/Strep2%10 mL Lipid-free media (store at 4°C for up to 3 months, sterile) Note: This commercially available FCS is depleted from lipids using a fumed silica precipitation method, which ensures a cholesterol level lower than 10 mg/100 mL. RPMI lipid transfer media (store at 4°C for up to 1 week, sterile)ReagentFinal concentrationAmount for 50 mLRPMI culture mediumN/A49.9 mLBSA0.1%50 μLCSF-110 ng/mL50 μL RPMI lipid transfer media (store at 4°C for up to 1 week, sterile) Washing buffer (store at 4°C for up to 3 months, sterile)ReagentFinal concentrationAmount for 500 mLPBSN/A497.5 mLBSA0.5%2.5 mL Washing buffer (store at 4°C for up to 3 months, sterile) Zombie aqua live/dead staining solution (prepare fresh)ReagentFinal concentrationAmount for 100 μLPBSN/A99.5 mLZombie aqua1:2000.5 μL Zombie aqua live/dead staining solution (prepare fresh) PFA fixation solution - lipid transfer (prepare fresh)ReagentFinal concentrationAmount for 1 mLPBSN/A812.5 μL16% PFA solution3%187.5 μL PFA fixation solution - lipid transfer (prepare fresh) Permeabilization solution - lipid transfer (store at 20°C)ReagentFinal concentrationAmount for 100 mLPBSN/A99.99 mLTriton0.01%10 μL Permeabilization solution - lipid transfer (store at 20°C) 1× Saponin + azide buffer (SAB) (store at 4°C for up to 6 months, sterile)ReagentFinal concentrationAmount for 1 mLPBSN/A891 μLBSA–9 μLClick-iT saponin-based permeabilization and wash reagent (from Click-iT EdU Alexa Fluor 647 Flow Cytometry Assay Kit)1:10100 μL 1× Saponin + azide buffer (SAB) (store at 4°C for up to 6 months, sterile) Reaction buffer G (prepare fresh)ReagentFinal concentrationAmount for 100 μLDeionized waterN/A90 μL10X Reaction buffer G (from Click-iT EdU Alexa Fluor 647 Flow Cytometry Assay Kit)1:1010 μL Reaction buffer G (prepare fresh) Click-it reaction solution (prepare fresh)ReagentFinal concentrationAmount for 100 μLPBS–87.5 μLCuSO4 (from Click-iT EdU Alexa Fluor 647 Flow Cytometry Assay Kit)40 μM2 μLAlexa 647 azide (from Click-iT EdU Alexa Fluor 647 Flow Cytometry Assay Kit)1:2000.5 μLReaction buffer G (see above)1:1010 μL Click-it reaction solution (prepare fresh) CD11b removal beads mixture (prepare fresh)ReagentFinal concentrationAmount for one tumorFlow cytometry staining Buffer (FB)N/A1900 μLCD11b beads1:20100 μL CD11b removal beads mixture (prepare fresh) Step-by-step method details Preparation of single-cell suspension from murine tumor tissue for downstream LLM flow cytometry-based sorting and analyses, or for generation of cell lines Timing: 2.5 h This section outlines the standard procedure to process tumor tissues for use in all downstream analyses described later in this protocol. In addition, we describe how to simultaneously isolate tumor interstitial fluid (TIF) from the tumor sample for lipidomic analyses. 1.Isolate tumor tissue.a.Remove as much healthy tissue as possible using a scalpel as shown in Figure 1A. Brain tumor tissue can be recognized by its darker color due to aberrant blood vessel growth and formation of necrotic areas compared to healthy tissue.b.Place isolated tumor tissue in empty 15 mL tube, place on ice. Isolate tumor tissue.a.Remove as much healthy tissue as possible using a scalpel as shown in Figure 1A. Brain tumor tissue can be recognized by its darker color due to aberrant blood vessel growth and formation of necrotic areas compared to healthy tissue.b.Place isolated tumor tissue in empty 15 mL tube, place on ice. a.Remove as much healthy tissue as possible using a scalpel as shown in Figure 1A. Brain tumor tissue can be recognized by its darker color due to aberrant blood vessel growth and formation of necrotic areas compared to healthy tissue. Remove as much healthy tissue as possible using a scalpel as shown in Figure 1A. Brain tumor tissue can be recognized by its darker color due to aberrant blood vessel growth and formation of necrotic areas compared to healthy tissue. b.Place isolated tumor tissue in empty 15 mL tube, place on ice. Place isolated tumor tissue in empty 15 mL tube, place on ice. CRITICAL: To improve the viability of the dissociated tumor cells, make sure samples are on ice during and in between each step unless stated otherwise. CRITICAL: If the goal of the tumor dissociation is to generate a cell line or perform an ex vivo assay, each step must be performed in a flow cabinet under sterile conditions to prevent contamination of the cell line. Note: A measurement of the tumor size (depending on the tumor type, using MRI scans, calipers, bioluminescence, weight, etc.) should be recorded for future reference, since variations in tumor size can impact the readout of the experiment. 2.Collect TIF.Note: Although not required for preparing the single cell suspension for downstream analysis of LLMs, collecting and performing lipidomic analyses on the tumor interstitial fluid provides important information about the lipid content in the tumor micro-environment (TME). These results may provide insights about the source and fate of these lipids in the context of metabolic exchanges between macrophages and tumor cells.a.Pre-cool the centrifuge to 4°C.b.Cut off quarter of 20 μm Nylon membrane filter and put on top of Eppendorf tube.Alternatives: This protocol is designed to isolate TIF from a relatively small tumor fragment (around 90 mm3). For larger tumor pieces, use a 15 mL tube with whole filter instead of an Eppendorf tube.c.Label Eppendorf tube and take note of its weight.CRITICAL: Weighting the isolated tumor tissue is important for normalization of the data acquired from analyzing the TIF.d.Place dissected tumor in the middle of the membrane filter on top of an opened Eppendorf tube as seen in Figure 1B, close the tube and weigh again.e.Note the weight of the Eppendorf tube with the tumor sample.i.Tumor mass = (Eppendorf tube with tumor piece) − Eppendorf tube.Optional: For smaller tumors which hold little to no fluids, use forceps to briefly rinse the tumor fragment in PBS (after tumor weight has been measured), before placing it back in the cap of an Eppendorf/15 mL tube containing the filter.CRITICAL: Make sure that the filter is placed correctly so that the tumor cannot go through it during centrifugation.f.Spin down at 400 g for 15 min at 4°C.g.Transfer supernatant to new Eppendorf tube.CRITICAL: A pellet of blood can be spotted at the bottom of the Eppendorf tube. Pipet out as much TIF as possible without disturbing the pellet to prevent blood from contaminating the sample, as it will interfere with the data analysis of the TIF.h.Snap freeze the TIF sample(s) on dry ice, transfer to −80°C for storage (samples can be stored for up to 6 months). Collect TIF.Note: Although not required for preparing the single cell suspension for downstream analysis of LLMs, collecting and performing lipidomic analyses on the tumor interstitial fluid provides important information about the lipid content in the tumor micro-environment (TME). These results may provide insights about the source and fate of these lipids in the context of metabolic exchanges between macrophages and tumor cells.a.Pre-cool the centrifuge to 4°C.b.Cut off quarter of 20 μm Nylon membrane filter and put on top of Eppendorf tube.Alternatives: This protocol is designed to isolate TIF from a relatively small tumor fragment (around 90 mm3). For larger tumor pieces, use a 15 mL tube with whole filter instead of an Eppendorf tube.c.Label Eppendorf tube and take note of its weight.CRITICAL: Weighting the isolated tumor tissue is important for normalization of the data acquired from analyzing the TIF.d.Place dissected tumor in the middle of the membrane filter on top of an opened Eppendorf tube as seen in Figure 1B, close the tube and weigh again.e.Note the weight of the Eppendorf tube with the tumor sample.i.Tumor mass = (Eppendorf tube with tumor piece) − Eppendorf tube.Optional: For smaller tumors which hold little to no fluids, use forceps to briefly rinse the tumor fragment in PBS (after tumor weight has been measured), before placing it back in the cap of an Eppendorf/15 mL tube containing the filter.CRITICAL: Make sure that the filter is placed correctly so that the tumor cannot go through it during centrifugation.f.Spin down at 400 g for 15 min at 4°C.g.Transfer supernatant to new Eppendorf tube.CRITICAL: A pellet of blood can be spotted at the bottom of the Eppendorf tube. Pipet out as much TIF as possible without disturbing the pellet to prevent blood from contaminating the sample, as it will interfere with the data analysis of the TIF.h.Snap freeze the TIF sample(s) on dry ice, transfer to −80°C for storage (samples can be stored for up to 6 months). Note: Although not required for preparing the single cell suspension for downstream analysis of LLMs, collecting and performing lipidomic analyses on the tumor interstitial fluid provides important information about the lipid content in the tumor micro-environment (TME). These results may provide insights about the source and fate of these lipids in the context of metabolic exchanges between macrophages and tumor cells. a.Pre-cool the centrifuge to 4°C. Pre-cool the centrifuge to 4°C. b.Cut off quarter of 20 μm Nylon membrane filter and put on top of Eppendorf tube.Alternatives: This protocol is designed to isolate TIF from a relatively small tumor fragment (around 90 mm3). For larger tumor pieces, use a 15 mL tube with whole filter instead of an Eppendorf tube. Cut off quarter of 20 μm Nylon membrane filter and put on top of Eppendorf tube.Alternatives: This protocol is designed to isolate TIF from a relatively small tumor fragment (around 90 mm3). For larger tumor pieces, use a 15 mL tube with whole filter instead of an Eppendorf tube. Alternatives: This protocol is designed to isolate TIF from a relatively small tumor fragment (around 90 mm3). For larger tumor pieces, use a 15 mL tube with whole filter instead of an Eppendorf tube. c.Label Eppendorf tube and take note of its weight.CRITICAL: Weighting the isolated tumor tissue is important for normalization of the data acquired from analyzing the TIF. Label Eppendorf tube and take note of its weight.CRITICAL: Weighting the isolated tumor tissue is important for normalization of the data acquired from analyzing the TIF. CRITICAL: Weighting the isolated tumor tissue is important for normalization of the data acquired from analyzing the TIF. d.Place dissected tumor in the middle of the membrane filter on top of an opened Eppendorf tube as seen in Figure 1B, close the tube and weigh again. Place dissected tumor in the middle of the membrane filter on top of an opened Eppendorf tube as seen in Figure 1B, close the tube and weigh again. e.Note the weight of the Eppendorf tube with the tumor sample.i.Tumor mass = (Eppendorf tube with tumor piece) − Eppendorf tube.Optional: For smaller tumors which hold little to no fluids, use forceps to briefly rinse the tumor fragment in PBS (after tumor weight has been measured), before placing it back in the cap of an Eppendorf/15 mL tube containing the filter.CRITICAL: Make sure that the filter is placed correctly so that the tumor cannot go through it during centrifugation. Note the weight of the Eppendorf tube with the tumor sample.i.Tumor mass = (Eppendorf tube with tumor piece) − Eppendorf tube.Optional: For smaller tumors which hold little to no fluids, use forceps to briefly rinse the tumor fragment in PBS (after tumor weight has been measured), before placing it back in the cap of an Eppendorf/15 mL tube containing the filter.CRITICAL: Make sure that the filter is placed correctly so that the tumor cannot go through it during centrifugation. i.Tumor mass = (Eppendorf tube with tumor piece) − Eppendorf tube.Optional: For smaller tumors which hold little to no fluids, use forceps to briefly rinse the tumor fragment in PBS (after tumor weight has been measured), before placing it back in the cap of an Eppendorf/15 mL tube containing the filter.CRITICAL: Make sure that the filter is placed correctly so that the tumor cannot go through it during centrifugation. Tumor mass = (Eppendorf tube with tumor piece) − Eppendorf tube.Optional: For smaller tumors which hold little to no fluids, use forceps to briefly rinse the tumor fragment in PBS (after tumor weight has been measured), before placing it back in the cap of an Eppendorf/15 mL tube containing the filter.CRITICAL: Make sure that the filter is placed correctly so that the tumor cannot go through it during centrifugation. Optional: For smaller tumors which hold little to no fluids, use forceps to briefly rinse the tumor fragment in PBS (after tumor weight has been measured), before placing it back in the cap of an Eppendorf/15 mL tube containing the filter. CRITICAL: Make sure that the filter is placed correctly so that the tumor cannot go through it during centrifugation. f.Spin down at 400 g for 15 min at 4°C. Spin down at 400 g for 15 min at 4°C. g.Transfer supernatant to new Eppendorf tube.CRITICAL: A pellet of blood can be spotted at the bottom of the Eppendorf tube. Pipet out as much TIF as possible without disturbing the pellet to prevent blood from contaminating the sample, as it will interfere with the data analysis of the TIF. Transfer supernatant to new Eppendorf tube.CRITICAL: A pellet of blood can be spotted at the bottom of the Eppendorf tube. Pipet out as much TIF as possible without disturbing the pellet to prevent blood from contaminating the sample, as it will interfere with the data analysis of the TIF. CRITICAL: A pellet of blood can be spotted at the bottom of the Eppendorf tube. Pipet out as much TIF as possible without disturbing the pellet to prevent blood from contaminating the sample, as it will interfere with the data analysis of the TIF. h.Snap freeze the TIF sample(s) on dry ice, transfer to −80°C for storage (samples can be stored for up to 6 months). Snap freeze the TIF sample(s) on dry ice, transfer to −80°C for storage (samples can be stored for up to 6 months). 3.Collect tumor tissue from the cap of Eppendorf tube and transfer to 10 mm dish on ice. Collect tumor tissue from the cap of Eppendorf tube and transfer to 10 mm dish on ice. 4.Prepare dissociation mixture in gentleMACS C-tube according to manufacturer’s instructions (Brain Tumor Dissociation Kit, Miltenyi Biotec, see materials and equipment section). Prepare dissociation mixture in gentleMACS C-tube according to manufacturer’s instructions (Brain Tumor Dissociation Kit, Miltenyi Biotec, see materials and equipment section). Alternatives: This dissociation kit is specifically designed for the dissociation of brain tumors. Alternative dissociation kits suited to the tissue of interest can be found in the manufacturer’s catalogue. 5.Cut tumor tissue in pieces of approximately 1 mm3 and place in C-tube. Cut tumor tissue in pieces of approximately 1 mm3 and place in C-tube. 6.Run 37C_m_TDK_1 program on gentleMACS octo-dissociator. Run 37C_m_TDK_1 program on gentleMACS octo-dissociator. Alternatives: This program is specifically designed to dissociate murine brain tissue. Alternative programs better suited to the tissue of interest can be found in the manufacturer’s instructions. 7.Prepare single cell suspension.a.Add 5 mL of cold HBSS to the dissociated tumor suspension.b.Transfer and filter the cell suspension through a 40 μm filter placed on top of a 50 mL tube.c.Rinse the C-tube with an additional 5 mL of cold HBSS, and transfer to the same 50 mL tube topped with a 40 μm filter.d.Use the rubber end of a 10 mL syringe to push residual tissue through the 40 μm filter.e.Wash filter with 20 mL cold HBSS.f.Spin down at 300 g for 5 min at 4°C. Prepare single cell suspension.a.Add 5 mL of cold HBSS to the dissociated tumor suspension.b.Transfer and filter the cell suspension through a 40 μm filter placed on top of a 50 mL tube.c.Rinse the C-tube with an additional 5 mL of cold HBSS, and transfer to the same 50 mL tube topped with a 40 μm filter.d.Use the rubber end of a 10 mL syringe to push residual tissue through the 40 μm filter.e.Wash filter with 20 mL cold HBSS.f.Spin down at 300 g for 5 min at 4°C. a.Add 5 mL of cold HBSS to the dissociated tumor suspension. Add 5 mL of cold HBSS to the dissociated tumor suspension. b.Transfer and filter the cell suspension through a 40 μm filter placed on top of a 50 mL tube. Transfer and filter the cell suspension through a 40 μm filter placed on top of a 50 mL tube. c.Rinse the C-tube with an additional 5 mL of cold HBSS, and transfer to the same 50 mL tube topped with a 40 μm filter. Rinse the C-tube with an additional 5 mL of cold HBSS, and transfer to the same 50 mL tube topped with a 40 μm filter. d.Use the rubber end of a 10 mL syringe to push residual tissue through the 40 μm filter. Use the rubber end of a 10 mL syringe to push residual tissue through the 40 μm filter. e.Wash filter with 20 mL cold HBSS. Wash filter with 20 mL cold HBSS. f.Spin down at 300 g for 5 min at 4°C. Spin down at 300 g for 5 min at 4°C. 8.Remove supernatant and resuspend in the following solutions (depending on downstream experiment or analysis):a.For tumor cell line generation:i.Resuspend pellet in 4 mL maintenance media (see materials and equipment section) and transfer to a T25 flask.ii.Place flask in 37°C incubator.CRITICAL: Refresh media daily with maintenance media and freeze down multiple vials (at least 30) after expanding cell lines extensively (7–9 passages). A minimum of 7 passages is needed to ensure that only tumor cells have expanded in the cell lines used in experiments.10 To limit batch-to-batch variation, it is recommended to perform phenotypic characterizations on one of these vials after thawing (for instance, qPCR for genes that are expected to be expressed by the cell lines in all batches; or any routine experiment relevant to the functions of the particular cell type studied) before use in in vitro experiments, and to not re-freeze a batch after thawing (as daughter cell lines may display an altered phenotype).b.For LLM flow cytometry analysis or purification (See Step 9).i.Resuspend in 1 mL Flow cytometry staining buffer (FB) (see materials and equipment section).c.For ex vivo assay (See Step 59).i.Resuspend in 1 mL sterile FB. Remove supernatant and resuspend in the following solutions (depending on downstream experiment or analysis):a.For tumor cell line generation:i.Resuspend pellet in 4 mL maintenance media (see materials and equipment section) and transfer to a T25 flask.ii.Place flask in 37°C incubator.CRITICAL: Refresh media daily with maintenance media and freeze down multiple vials (at least 30) after expanding cell lines extensively (7–9 passages). A minimum of 7 passages is needed to ensure that only tumor cells have expanded in the cell lines used in experiments.10 To limit batch-to-batch variation, it is recommended to perform phenotypic characterizations on one of these vials after thawing (for instance, qPCR for genes that are expected to be expressed by the cell lines in all batches; or any routine experiment relevant to the functions of the particular cell type studied) before use in in vitro experiments, and to not re-freeze a batch after thawing (as daughter cell lines may display an altered phenotype).b.For LLM flow cytometry analysis or purification (See Step 9).i.Resuspend in 1 mL Flow cytometry staining buffer (FB) (see materials and equipment section).c.For ex vivo assay (See Step 59).i.Resuspend in 1 mL sterile FB. a.For tumor cell line generation:i.Resuspend pellet in 4 mL maintenance media (see materials and equipment section) and transfer to a T25 flask.ii.Place flask in 37°C incubator.CRITICAL: Refresh media daily with maintenance media and freeze down multiple vials (at least 30) after expanding cell lines extensively (7–9 passages). A minimum of 7 passages is needed to ensure that only tumor cells have expanded in the cell lines used in experiments.10 To limit batch-to-batch variation, it is recommended to perform phenotypic characterizations on one of these vials after thawing (for instance, qPCR for genes that are expected to be expressed by the cell lines in all batches; or any routine experiment relevant to the functions of the particular cell type studied) before use in in vitro experiments, and to not re-freeze a batch after thawing (as daughter cell lines may display an altered phenotype). For tumor cell line generation:i.Resuspend pellet in 4 mL maintenance media (see materials and equipment section) and transfer to a T25 flask.ii.Place flask in 37°C incubator.CRITICAL: Refresh media daily with maintenance media and freeze down multiple vials (at least 30) after expanding cell lines extensively (7–9 passages). A minimum of 7 passages is needed to ensure that only tumor cells have expanded in the cell lines used in experiments.10 To limit batch-to-batch variation, it is recommended to perform phenotypic characterizations on one of these vials after thawing (for instance, qPCR for genes that are expected to be expressed by the cell lines in all batches; or any routine experiment relevant to the functions of the particular cell type studied) before use in in vitro experiments, and to not re-freeze a batch after thawing (as daughter cell lines may display an altered phenotype). i.Resuspend pellet in 4 mL maintenance media (see materials and equipment section) and transfer to a T25 flask. Resuspend pellet in 4 mL maintenance media (see materials and equipment section) and transfer to a T25 flask. ii.Place flask in 37°C incubator.CRITICAL: Refresh media daily with maintenance media and freeze down multiple vials (at least 30) after expanding cell lines extensively (7–9 passages). A minimum of 7 passages is needed to ensure that only tumor cells have expanded in the cell lines used in experiments.10 To limit batch-to-batch variation, it is recommended to perform phenotypic characterizations on one of these vials after thawing (for instance, qPCR for genes that are expected to be expressed by the cell lines in all batches; or any routine experiment relevant to the functions of the particular cell type studied) before use in in vitro experiments, and to not re-freeze a batch after thawing (as daughter cell lines may display an altered phenotype). Place flask in 37°C incubator.CRITICAL: Refresh media daily with maintenance media and freeze down multiple vials (at least 30) after expanding cell lines extensively (7–9 passages). A minimum of 7 passages is needed to ensure that only tumor cells have expanded in the cell lines used in experiments.10 To limit batch-to-batch variation, it is recommended to perform phenotypic characterizations on one of these vials after thawing (for instance, qPCR for genes that are expected to be expressed by the cell lines in all batches; or any routine experiment relevant to the functions of the particular cell type studied) before use in in vitro experiments, and to not re-freeze a batch after thawing (as daughter cell lines may display an altered phenotype). CRITICAL: Refresh media daily with maintenance media and freeze down multiple vials (at least 30) after expanding cell lines extensively (7–9 passages). A minimum of 7 passages is needed to ensure that only tumor cells have expanded in the cell lines used in experiments.10 To limit batch-to-batch variation, it is recommended to perform phenotypic characterizations on one of these vials after thawing (for instance, qPCR for genes that are expected to be expressed by the cell lines in all batches; or any routine experiment relevant to the functions of the particular cell type studied) before use in in vitro experiments, and to not re-freeze a batch after thawing (as daughter cell lines may display an altered phenotype). b.For LLM flow cytometry analysis or purification (See Step 9).i.Resuspend in 1 mL Flow cytometry staining buffer (FB) (see materials and equipment section). For LLM flow cytometry analysis or purification (See Step 9).i.Resuspend in 1 mL Flow cytometry staining buffer (FB) (see materials and equipment section). i.Resuspend in 1 mL Flow cytometry staining buffer (FB) (see materials and equipment section). Resuspend in 1 mL Flow cytometry staining buffer (FB) (see materials and equipment section). c.For ex vivo assay (See Step 59).i.Resuspend in 1 mL sterile FB. For ex vivo assay (See Step 59).i.Resuspend in 1 mL sterile FB. i.Resuspend in 1 mL sterile FB. Resuspend in 1 mL sterile FB. Macro dissection and collection of tumor interstitial fluid (A) To reduce variability and improve reliability of the data acquired from the tumor tissue, remove as much healthy tissue as possible using a scalpel. (B) Transfer the isolated tumor tissue to a pre-weighted Eppendorf tube with a Nylon filter membrane before weighting the tumor tissue for normalization. In vivo LLM flow cytometry analysis and isolation for downstream multi-omics analysis Timing: ∼4 h This section outlines how to further process the prepared single-cell suspension from tumor tissue to perform phenotypic analyses and isolate lipid-laden macrophages (LLMs) using flow cytometry. The isolation of LLMs from tumor tissue allows further characterization using multi-omics analyses, such as lipidomics and bulk- or single cell RNA sequencing. 9.Isolate tumor tissue and prepare single-cell suspension (as described in Steps 1 to 8).Optional: If working with brain tumor tissues, a myelin removal step can be performed by negative selection. For this, incubate single cell suspension in myelin removal bead solution (see materials and equipment section) for 15 min on ice. Add 18 mL FB and spin down at 300 g for 5 min at 4°C. Resuspend pellet in 1 mL FB, run through magnetic LS column and collect flow-through. Wash the column 3 times with 2 mL FB and collect flow-through. Spin down flow-through at 300 g for 5 min at 4°C.a.Resuspend in 200 μL FB and transfer single cell suspension to a 96-well plate (round bottom) to proceed with flow cytometry staining.CRITICAL: Split single cell suspension into multiple wells for compensation samples that require use of cells (i.e. unstained sample, live/dead and BODIPY compensation samples).b.Centrifuge the plate at 550 g for 2 min and remove supernatant by swiftly inverting plate and tapping it dry on a paper towel.c.Resuspend pellet in 150 μL red blood cell lysis buffer (see materials and equipment section), incubate for 1–2 min at RT.d.Centrifuge the plate at 550 g for 2 min. Repeat Steps 9c and 9d, if necessary, until the pellet becomes white.e.Subsequently wash pellet with 150 μL FB, spin down plate at 550 g for 2 min and remove supernatant. Isolate tumor tissue and prepare single-cell suspension (as described in Steps 1 to 8).Optional: If working with brain tumor tissues, a myelin removal step can be performed by negative selection. For this, incubate single cell suspension in myelin removal bead solution (see materials and equipment section) for 15 min on ice. Add 18 mL FB and spin down at 300 g for 5 min at 4°C. Resuspend pellet in 1 mL FB, run through magnetic LS column and collect flow-through. Wash the column 3 times with 2 mL FB and collect flow-through. Spin down flow-through at 300 g for 5 min at 4°C.a.Resuspend in 200 μL FB and transfer single cell suspension to a 96-well plate (round bottom) to proceed with flow cytometry staining.CRITICAL: Split single cell suspension into multiple wells for compensation samples that require use of cells (i.e. unstained sample, live/dead and BODIPY compensation samples).b.Centrifuge the plate at 550 g for 2 min and remove supernatant by swiftly inverting plate and tapping it dry on a paper towel.c.Resuspend pellet in 150 μL red blood cell lysis buffer (see materials and equipment section), incubate for 1–2 min at RT.d.Centrifuge the plate at 550 g for 2 min. Repeat Steps 9c and 9d, if necessary, until the pellet becomes white.e.Subsequently wash pellet with 150 μL FB, spin down plate at 550 g for 2 min and remove supernatant. Optional: If working with brain tumor tissues, a myelin removal step can be performed by negative selection. For this, incubate single cell suspension in myelin removal bead solution (see materials and equipment section) for 15 min on ice. Add 18 mL FB and spin down at 300 g for 5 min at 4°C. Resuspend pellet in 1 mL FB, run through magnetic LS column and collect flow-through. Wash the column 3 times with 2 mL FB and collect flow-through. Spin down flow-through at 300 g for 5 min at 4°C. a.Resuspend in 200 μL FB and transfer single cell suspension to a 96-well plate (round bottom) to proceed with flow cytometry staining.CRITICAL: Split single cell suspension into multiple wells for compensation samples that require use of cells (i.e. unstained sample, live/dead and BODIPY compensation samples). Resuspend in 200 μL FB and transfer single cell suspension to a 96-well plate (round bottom) to proceed with flow cytometry staining.CRITICAL: Split single cell suspension into multiple wells for compensation samples that require use of cells (i.e. unstained sample, live/dead and BODIPY compensation samples). CRITICAL: Split single cell suspension into multiple wells for compensation samples that require use of cells (i.e. unstained sample, live/dead and BODIPY compensation samples). b.Centrifuge the plate at 550 g for 2 min and remove supernatant by swiftly inverting plate and tapping it dry on a paper towel. Centrifuge the plate at 550 g for 2 min and remove supernatant by swiftly inverting plate and tapping it dry on a paper towel. c.Resuspend pellet in 150 μL red blood cell lysis buffer (see materials and equipment section), incubate for 1–2 min at RT. Resuspend pellet in 150 μL red blood cell lysis buffer (see materials and equipment section), incubate for 1–2 min at RT. d.Centrifuge the plate at 550 g for 2 min. Repeat Steps 9c and 9d, if necessary, until the pellet becomes white. Centrifuge the plate at 550 g for 2 min. Repeat Steps 9c and 9d, if necessary, until the pellet becomes white. e.Subsequently wash pellet with 150 μL FB, spin down plate at 550 g for 2 min and remove supernatant. Subsequently wash pellet with 150 μL FB, spin down plate at 550 g for 2 min and remove supernatant. 10.Sample blocking and antibody staining.a.Block non-specific binding by resuspending samples in 75 μL Fc-blocking reagent (see materials and equipment section) and incubate for 15–30 min on ice.b.Prepare antibody mixes according to the relevant procedure (see materials and equipment section):i.For flow cytometry analysis of macrophage phenotype and TME, prepare antibody mix 1.ii.For cell sorting and single-cell RNA sequencing of the whole TME, prepare antibody mix 2.iii.For sorting and isolating LLMs, prepare antibody mix 3.Note: In this protocol, we describe an antibody panel tailored to investigate the tumor myeloid compartment of glioblastoma brain tumors. For example, CD49d is used to separate tissue resident macrophages (CD49d-) from monocyte-derived macrophages (CD49d+) within the brain (Figure 2A).5 When assessing LLMs within tissues other than brain, the markers used to distinguish recruited from resident macrophages must be adapted accordingly. For example, when analyzing murine HCC tissue, F4-80 can be used as a marker to separate between tissue resident macrophages in the liver, also known as Kupffer cells, from MDMs (Figure 2B).c.Centrifuge plate at 550 g for 2 min and remove supernatant.d.Add 75 μL of the appropriate antibody mix to wells that are to be stained with the complete panel and incubate for 15–30 min on ice, protected from light.CRITICAL: Instead of the antibody mix, add either 100 μL FB to the unstained and BODIPY compensation sample, or 100 μL fixation solution (see materials and equipment section) to artificially create a “dead” cell population for the live/dead compensation control sample during the antibody staining.e.Spin down at 550 g for 2 min and remove supernatant, wash 1x in FB and 1x in PBS.Note: It is important to wash cells in PBS prior to live/dead staining, since residual serum may affect Zombie dye staining efficacy. Sample blocking and antibody staining.a.Block non-specific binding by resuspending samples in 75 μL Fc-blocking reagent (see materials and equipment section) and incubate for 15–30 min on ice.b.Prepare antibody mixes according to the relevant procedure (see materials and equipment section):i.For flow cytometry analysis of macrophage phenotype and TME, prepare antibody mix 1.ii.For cell sorting and single-cell RNA sequencing of the whole TME, prepare antibody mix 2.iii.For sorting and isolating LLMs, prepare antibody mix 3.Note: In this protocol, we describe an antibody panel tailored to investigate the tumor myeloid compartment of glioblastoma brain tumors. For example, CD49d is used to separate tissue resident macrophages (CD49d-) from monocyte-derived macrophages (CD49d+) within the brain (Figure 2A).5 When assessing LLMs within tissues other than brain, the markers used to distinguish recruited from resident macrophages must be adapted accordingly. For example, when analyzing murine HCC tissue, F4-80 can be used as a marker to separate between tissue resident macrophages in the liver, also known as Kupffer cells, from MDMs (Figure 2B).c.Centrifuge plate at 550 g for 2 min and remove supernatant.d.Add 75 μL of the appropriate antibody mix to wells that are to be stained with the complete panel and incubate for 15–30 min on ice, protected from light.CRITICAL: Instead of the antibody mix, add either 100 μL FB to the unstained and BODIPY compensation sample, or 100 μL fixation solution (see materials and equipment section) to artificially create a “dead” cell population for the live/dead compensation control sample during the antibody staining.e.Spin down at 550 g for 2 min and remove supernatant, wash 1x in FB and 1x in PBS.Note: It is important to wash cells in PBS prior to live/dead staining, since residual serum may affect Zombie dye staining efficacy. a.Block non-specific binding by resuspending samples in 75 μL Fc-blocking reagent (see materials and equipment section) and incubate for 15–30 min on ice. Block non-specific binding by resuspending samples in 75 μL Fc-blocking reagent (see materials and equipment section) and incubate for 15–30 min on ice. b.Prepare antibody mixes according to the relevant procedure (see materials and equipment section):i.For flow cytometry analysis of macrophage phenotype and TME, prepare antibody mix 1.ii.For cell sorting and single-cell RNA sequencing of the whole TME, prepare antibody mix 2.iii.For sorting and isolating LLMs, prepare antibody mix 3.Note: In this protocol, we describe an antibody panel tailored to investigate the tumor myeloid compartment of glioblastoma brain tumors. For example, CD49d is used to separate tissue resident macrophages (CD49d-) from monocyte-derived macrophages (CD49d+) within the brain (Figure 2A).5 When assessing LLMs within tissues other than brain, the markers used to distinguish recruited from resident macrophages must be adapted accordingly. For example, when analyzing murine HCC tissue, F4-80 can be used as a marker to separate between tissue resident macrophages in the liver, also known as Kupffer cells, from MDMs (Figure 2B). Prepare antibody mixes according to the relevant procedure (see materials and equipment section):i.For flow cytometry analysis of macrophage phenotype and TME, prepare antibody mix 1.ii.For cell sorting and single-cell RNA sequencing of the whole TME, prepare antibody mix 2.iii.For sorting and isolating LLMs, prepare antibody mix 3.Note: In this protocol, we describe an antibody panel tailored to investigate the tumor myeloid compartment of glioblastoma brain tumors. For example, CD49d is used to separate tissue resident macrophages (CD49d-) from monocyte-derived macrophages (CD49d+) within the brain (Figure 2A).5 When assessing LLMs within tissues other than brain, the markers used to distinguish recruited from resident macrophages must be adapted accordingly. For example, when analyzing murine HCC tissue, F4-80 can be used as a marker to separate between tissue resident macrophages in the liver, also known as Kupffer cells, from MDMs (Figure 2B). i.For flow cytometry analysis of macrophage phenotype and TME, prepare antibody mix 1. For flow cytometry analysis of macrophage phenotype and TME, prepare antibody mix 1. ii.For cell sorting and single-cell RNA sequencing of the whole TME, prepare antibody mix 2. For cell sorting and single-cell RNA sequencing of the whole TME, prepare antibody mix 2. iii.For sorting and isolating LLMs, prepare antibody mix 3.Note: In this protocol, we describe an antibody panel tailored to investigate the tumor myeloid compartment of glioblastoma brain tumors. For example, CD49d is used to separate tissue resident macrophages (CD49d-) from monocyte-derived macrophages (CD49d+) within the brain (Figure 2A).5 When assessing LLMs within tissues other than brain, the markers used to distinguish recruited from resident macrophages must be adapted accordingly. For example, when analyzing murine HCC tissue, F4-80 can be used as a marker to separate between tissue resident macrophages in the liver, also known as Kupffer cells, from MDMs (Figure 2B). For sorting and isolating LLMs, prepare antibody mix 3.Note: In this protocol, we describe an antibody panel tailored to investigate the tumor myeloid compartment of glioblastoma brain tumors. For example, CD49d is used to separate tissue resident macrophages (CD49d-) from monocyte-derived macrophages (CD49d+) within the brain (Figure 2A).5 When assessing LLMs within tissues other than brain, the markers used to distinguish recruited from resident macrophages must be adapted accordingly. For example, when analyzing murine HCC tissue, F4-80 can be used as a marker to separate between tissue resident macrophages in the liver, also known as Kupffer cells, from MDMs (Figure 2B). Note: In this protocol, we describe an antibody panel tailored to investigate the tumor myeloid compartment of glioblastoma brain tumors. For example, CD49d is used to separate tissue resident macrophages (CD49d-) from monocyte-derived macrophages (CD49d+) within the brain (Figure 2A).5 When assessing LLMs within tissues other than brain, the markers used to distinguish recruited from resident macrophages must be adapted accordingly. For example, when analyzing murine HCC tissue, F4-80 can be used as a marker to separate between tissue resident macrophages in the liver, also known as Kupffer cells, from MDMs (Figure 2B). c.Centrifuge plate at 550 g for 2 min and remove supernatant. Centrifuge plate at 550 g for 2 min and remove supernatant. d.Add 75 μL of the appropriate antibody mix to wells that are to be stained with the complete panel and incubate for 15–30 min on ice, protected from light.CRITICAL: Instead of the antibody mix, add either 100 μL FB to the unstained and BODIPY compensation sample, or 100 μL fixation solution (see materials and equipment section) to artificially create a “dead” cell population for the live/dead compensation control sample during the antibody staining. Add 75 μL of the appropriate antibody mix to wells that are to be stained with the complete panel and incubate for 15–30 min on ice, protected from light.CRITICAL: Instead of the antibody mix, add either 100 μL FB to the unstained and BODIPY compensation sample, or 100 μL fixation solution (see materials and equipment section) to artificially create a “dead” cell population for the live/dead compensation control sample during the antibody staining. CRITICAL: Instead of the antibody mix, add either 100 μL FB to the unstained and BODIPY compensation sample, or 100 μL fixation solution (see materials and equipment section) to artificially create a “dead” cell population for the live/dead compensation control sample during the antibody staining. e.Spin down at 550 g for 2 min and remove supernatant, wash 1x in FB and 1x in PBS.Note: It is important to wash cells in PBS prior to live/dead staining, since residual serum may affect Zombie dye staining efficacy. Spin down at 550 g for 2 min and remove supernatant, wash 1x in FB and 1x in PBS.Note: It is important to wash cells in PBS prior to live/dead staining, since residual serum may affect Zombie dye staining efficacy. Note: It is important to wash cells in PBS prior to live/dead staining, since residual serum may affect Zombie dye staining efficacy. 11.Live/dead staining.a.Prepare Zombie NIR live/dead staining solution in PBS (see materials and equipment section).b.Add 50 μL of staining solution to cells. Resuspend and incubate for 15–30 min on ice and protect from light.CRITICAL: Instead of the Zombie NIR live/dead staining solution, add 50 μL PBS to the unstained and BODIPY compensation samples.c.Wash 1x with 150 μL FB and spin down at 550 g for 2 min.Note: For LLM flow cytometry-based sorting, the fixation and intracellular staining steps are not required. Proceed directly to BODIPY staining (Step 13) instead.Note: For scRNA-seq, immediately proceed to cell sorting and sequencing (Step 16). Live/dead staining.a.Prepare Zombie NIR live/dead staining solution in PBS (see materials and equipment section).b.Add 50 μL of staining solution to cells. Resuspend and incubate for 15–30 min on ice and protect from light.CRITICAL: Instead of the Zombie NIR live/dead staining solution, add 50 μL PBS to the unstained and BODIPY compensation samples.c.Wash 1x with 150 μL FB and spin down at 550 g for 2 min.Note: For LLM flow cytometry-based sorting, the fixation and intracellular staining steps are not required. Proceed directly to BODIPY staining (Step 13) instead.Note: For scRNA-seq, immediately proceed to cell sorting and sequencing (Step 16). a.Prepare Zombie NIR live/dead staining solution in PBS (see materials and equipment section). Prepare Zombie NIR live/dead staining solution in PBS (see materials and equipment section). b.Add 50 μL of staining solution to cells. Resuspend and incubate for 15–30 min on ice and protect from light.CRITICAL: Instead of the Zombie NIR live/dead staining solution, add 50 μL PBS to the unstained and BODIPY compensation samples. Add 50 μL of staining solution to cells. Resuspend and incubate for 15–30 min on ice and protect from light.CRITICAL: Instead of the Zombie NIR live/dead staining solution, add 50 μL PBS to the unstained and BODIPY compensation samples. CRITICAL: Instead of the Zombie NIR live/dead staining solution, add 50 μL PBS to the unstained and BODIPY compensation samples. c.Wash 1x with 150 μL FB and spin down at 550 g for 2 min.Note: For LLM flow cytometry-based sorting, the fixation and intracellular staining steps are not required. Proceed directly to BODIPY staining (Step 13) instead.Note: For scRNA-seq, immediately proceed to cell sorting and sequencing (Step 16). Wash 1x with 150 μL FB and spin down at 550 g for 2 min.Note: For LLM flow cytometry-based sorting, the fixation and intracellular staining steps are not required. Proceed directly to BODIPY staining (Step 13) instead.Note: For scRNA-seq, immediately proceed to cell sorting and sequencing (Step 16). Note: For LLM flow cytometry-based sorting, the fixation and intracellular staining steps are not required. Proceed directly to BODIPY staining (Step 13) instead. Note: For scRNA-seq, immediately proceed to cell sorting and sequencing (Step 16). 12.Fixation and intracellular staining.a.Resuspend cells in 100 μL fixation solution (see materials and equipment section) and incubate for 30 min at RT and protected from light.Pause point: After fixation, spin sample down at 550 g for 2 min, remove supernatant and resuspend in 100 μL FB. These samples can be stored for up to 48 h at 4°C before proceeding to the subsequent steps.b.Wash cells with permeabilization buffer (see materials and equipment section), spin down at 550 g for 2 min and discard supernatant.c.Prepare intracellular antibody mix 4 (see materials and equipment section).d.Resuspend cells in 50 μL of intracellular antibody mix and incubate for 15–30 min on ice protected from light.e.Wash cells in 150 μL FB, spin at 550 g for 2 min and discard supernatant. Fixation and intracellular staining.a.Resuspend cells in 100 μL fixation solution (see materials and equipment section) and incubate for 30 min at RT and protected from light.Pause point: After fixation, spin sample down at 550 g for 2 min, remove supernatant and resuspend in 100 μL FB. These samples can be stored for up to 48 h at 4°C before proceeding to the subsequent steps.b.Wash cells with permeabilization buffer (see materials and equipment section), spin down at 550 g for 2 min and discard supernatant.c.Prepare intracellular antibody mix 4 (see materials and equipment section).d.Resuspend cells in 50 μL of intracellular antibody mix and incubate for 15–30 min on ice protected from light.e.Wash cells in 150 μL FB, spin at 550 g for 2 min and discard supernatant. a.Resuspend cells in 100 μL fixation solution (see materials and equipment section) and incubate for 30 min at RT and protected from light.Pause point: After fixation, spin sample down at 550 g for 2 min, remove supernatant and resuspend in 100 μL FB. These samples can be stored for up to 48 h at 4°C before proceeding to the subsequent steps. Resuspend cells in 100 μL fixation solution (see materials and equipment section) and incubate for 30 min at RT and protected from light.Pause point: After fixation, spin sample down at 550 g for 2 min, remove supernatant and resuspend in 100 μL FB. These samples can be stored for up to 48 h at 4°C before proceeding to the subsequent steps. Pause point: After fixation, spin sample down at 550 g for 2 min, remove supernatant and resuspend in 100 μL FB. These samples can be stored for up to 48 h at 4°C before proceeding to the subsequent steps. b.Wash cells with permeabilization buffer (see materials and equipment section), spin down at 550 g for 2 min and discard supernatant. Wash cells with permeabilization buffer (see materials and equipment section), spin down at 550 g for 2 min and discard supernatant. c.Prepare intracellular antibody mix 4 (see materials and equipment section). Prepare intracellular antibody mix 4 (see materials and equipment section). d.Resuspend cells in 50 μL of intracellular antibody mix and incubate for 15–30 min on ice protected from light. Resuspend cells in 50 μL of intracellular antibody mix and incubate for 15–30 min on ice protected from light. e.Wash cells in 150 μL FB, spin at 550 g for 2 min and discard supernatant. Wash cells in 150 μL FB, spin at 550 g for 2 min and discard supernatant. 13.Prepare BODIPY staining solution and stain sample.a.Prepare BODIPY staining solution fresh (see materials and equipment section).b.Resuspend cells in 100 μL BODIPY staining solution and incubate for 20 min at 37°C.Note: Also add BODIPY solution to BODIPY compensation sample.Note: Although fixation before BODIPY staining generally leads to a lower BODIPY signal in cells, the relative lipid content in fixed cells can be assessed with BODIPY.c.Wash cells 2x in 150 μL FB and resuspend in 100 μL FB. Samples are now ready for flow cytometry analyses (Step 15) or sort (Step 16). Prepare BODIPY staining solution and stain sample.a.Prepare BODIPY staining solution fresh (see materials and equipment section).b.Resuspend cells in 100 μL BODIPY staining solution and incubate for 20 min at 37°C.Note: Also add BODIPY solution to BODIPY compensation sample.Note: Although fixation before BODIPY staining generally leads to a lower BODIPY signal in cells, the relative lipid content in fixed cells can be assessed with BODIPY.c.Wash cells 2x in 150 μL FB and resuspend in 100 μL FB. Samples are now ready for flow cytometry analyses (Step 15) or sort (Step 16). a.Prepare BODIPY staining solution fresh (see materials and equipment section). Prepare BODIPY staining solution fresh (see materials and equipment section). b.Resuspend cells in 100 μL BODIPY staining solution and incubate for 20 min at 37°C.Note: Also add BODIPY solution to BODIPY compensation sample.Note: Although fixation before BODIPY staining generally leads to a lower BODIPY signal in cells, the relative lipid content in fixed cells can be assessed with BODIPY. Resuspend cells in 100 μL BODIPY staining solution and incubate for 20 min at 37°C.Note: Also add BODIPY solution to BODIPY compensation sample.Note: Although fixation before BODIPY staining generally leads to a lower BODIPY signal in cells, the relative lipid content in fixed cells can be assessed with BODIPY. Note: Also add BODIPY solution to BODIPY compensation sample. Note: Although fixation before BODIPY staining generally leads to a lower BODIPY signal in cells, the relative lipid content in fixed cells can be assessed with BODIPY. c.Wash cells 2x in 150 μL FB and resuspend in 100 μL FB. Samples are now ready for flow cytometry analyses (Step 15) or sort (Step 16). Wash cells 2x in 150 μL FB and resuspend in 100 μL FB. Samples are now ready for flow cytometry analyses (Step 15) or sort (Step 16). 14.Preparation of compensation controls (single antibody stains).a.For each fluorophore, add one drop of UltraComp eBeads in 100 μL of FB in well of a 96-well plate.b.Add 0.5 μL of each antibody used to each well and resuspend.c.Incubate for 5 min on ice protected from light.d.Wash with 100 μL FB and resuspend in 100 μL FB. Compensation samples are now ready to use. Preparation of compensation controls (single antibody stains).a.For each fluorophore, add one drop of UltraComp eBeads in 100 μL of FB in well of a 96-well plate.b.Add 0.5 μL of each antibody used to each well and resuspend.c.Incubate for 5 min on ice protected from light.d.Wash with 100 μL FB and resuspend in 100 μL FB. Compensation samples are now ready to use. a.For each fluorophore, add one drop of UltraComp eBeads in 100 μL of FB in well of a 96-well plate. For each fluorophore, add one drop of UltraComp eBeads in 100 μL of FB in well of a 96-well plate. b.Add 0.5 μL of each antibody used to each well and resuspend. Add 0.5 μL of each antibody used to each well and resuspend. c.Incubate for 5 min on ice protected from light. Incubate for 5 min on ice protected from light. d.Wash with 100 μL FB and resuspend in 100 μL FB. Compensation samples are now ready to use. Wash with 100 μL FB and resuspend in 100 μL FB. Compensation samples are now ready to use. 15.Flow cytometry sample acquisition and data analysis.a.Using the proposed antibody panels in Step 10, samples can be acquired with flow cytometers that have the following 4 lasers: Violet (405 nm), Blue (488 nm), Yellow/Green (561 nm) and Red (640 nm), such as the BD Fortessa.b.Perform compensation using single stains prepared in Steps 11, 13 and 14.c.The acquired data can be analyzed using the FlowJo software. Gating strategy for the proposed myeloid panel can be found in Figure 2. Flow cytometry sample acquisition and data analysis.a.Using the proposed antibody panels in Step 10, samples can be acquired with flow cytometers that have the following 4 lasers: Violet (405 nm), Blue (488 nm), Yellow/Green (561 nm) and Red (640 nm), such as the BD Fortessa.b.Perform compensation using single stains prepared in Steps 11, 13 and 14.c.The acquired data can be analyzed using the FlowJo software. Gating strategy for the proposed myeloid panel can be found in Figure 2. a.Using the proposed antibody panels in Step 10, samples can be acquired with flow cytometers that have the following 4 lasers: Violet (405 nm), Blue (488 nm), Yellow/Green (561 nm) and Red (640 nm), such as the BD Fortessa. Using the proposed antibody panels in Step 10, samples can be acquired with flow cytometers that have the following 4 lasers: Violet (405 nm), Blue (488 nm), Yellow/Green (561 nm) and Red (640 nm), such as the BD Fortessa. b.Perform compensation using single stains prepared in Steps 11, 13 and 14. Perform compensation using single stains prepared in Steps 11, 13 and 14. c.The acquired data can be analyzed using the FlowJo software. Gating strategy for the proposed myeloid panel can be found in Figure 2. The acquired data can be analyzed using the FlowJo software. Gating strategy for the proposed myeloid panel can be found in Figure 2. 16.Cell sorting and downstream analysis.a.Single-cell RNA sequencing on whole single-cell suspension of tumor tissue.i.Sort live CD45+ and CD45− cells and collect in two separate Eppendorf tubes.ii.Wash 1x with 1 mL PBS, spin at 300 g for 5 min and discard supernatant.iii.Resuspend cells in 0.04% BSA in PBS, mix CD45+ and CD45− cells in a 1:1 ratio (1000 cells per μL) and proceed to sequencing.Note: The CD45+ and CD45− cells are mixed back in a 1:1 ratio to make sure both the tumor cells and immune cells are equally represented in the scRNA-seq dataset.Note: We recommend processing the single cell suspension with the GEM-X kit (10x), aiming for 1 × 104 target cells to ensure sufficient granularity in macrophage subsets.b.Bulk RNA sequencing or lipidomics downstream analysis on (non)-LLMs.i.Sort LLMs and non-LLMs according to the gating strategy depicted in Figure 2A. Process the collected cells, depending on the downstream analysis:ii.For lipidomics analyses, wash 1x with 1 mL PBS, spin at 300 g for 5 min and discard supernatant. Resuspend in 250 μL PBS, snap freeze on dry ice then store at −80°C.iii.For bulk RNA sequencing, homogenize 1–10 × 106 cells in 600 μL RLT lysis buffer; or 1 × 105–1 × 106 cells in 350 μL RLT lysis buffer; or 1 × 105 cells in 75 μL RLT lysis buffer. Store at −80°C. A minimum of 1 × 104 cells per population is recommended to ensure sufficient RNA for downstream analyses using Qiagen RNA Sequencing kits. Cell sorting and downstream analysis.a.Single-cell RNA sequencing on whole single-cell suspension of tumor tissue.i.Sort live CD45+ and CD45− cells and collect in two separate Eppendorf tubes.ii.Wash 1x with 1 mL PBS, spin at 300 g for 5 min and discard supernatant.iii.Resuspend cells in 0.04% BSA in PBS, mix CD45+ and CD45− cells in a 1:1 ratio (1000 cells per μL) and proceed to sequencing.Note: The CD45+ and CD45− cells are mixed back in a 1:1 ratio to make sure both the tumor cells and immune cells are equally represented in the scRNA-seq dataset.Note: We recommend processing the single cell suspension with the GEM-X kit (10x), aiming for 1 × 104 target cells to ensure sufficient granularity in macrophage subsets.b.Bulk RNA sequencing or lipidomics downstream analysis on (non)-LLMs.i.Sort LLMs and non-LLMs according to the gating strategy depicted in Figure 2A. Process the collected cells, depending on the downstream analysis:ii.For lipidomics analyses, wash 1x with 1 mL PBS, spin at 300 g for 5 min and discard supernatant. Resuspend in 250 μL PBS, snap freeze on dry ice then store at −80°C.iii.For bulk RNA sequencing, homogenize 1–10 × 106 cells in 600 μL RLT lysis buffer; or 1 × 105–1 × 106 cells in 350 μL RLT lysis buffer; or 1 × 105 cells in 75 μL RLT lysis buffer. Store at −80°C. A minimum of 1 × 104 cells per population is recommended to ensure sufficient RNA for downstream analyses using Qiagen RNA Sequencing kits. a.Single-cell RNA sequencing on whole single-cell suspension of tumor tissue.i.Sort live CD45+ and CD45− cells and collect in two separate Eppendorf tubes.ii.Wash 1x with 1 mL PBS, spin at 300 g for 5 min and discard supernatant.iii.Resuspend cells in 0.04% BSA in PBS, mix CD45+ and CD45− cells in a 1:1 ratio (1000 cells per μL) and proceed to sequencing.Note: The CD45+ and CD45− cells are mixed back in a 1:1 ratio to make sure both the tumor cells and immune cells are equally represented in the scRNA-seq dataset.Note: We recommend processing the single cell suspension with the GEM-X kit (10x), aiming for 1 × 104 target cells to ensure sufficient granularity in macrophage subsets. Single-cell RNA sequencing on whole single-cell suspension of tumor tissue.i.Sort live CD45+ and CD45− cells and collect in two separate Eppendorf tubes.ii.Wash 1x with 1 mL PBS, spin at 300 g for 5 min and discard supernatant.iii.Resuspend cells in 0.04% BSA in PBS, mix CD45+ and CD45− cells in a 1:1 ratio (1000 cells per μL) and proceed to sequencing.Note: The CD45+ and CD45− cells are mixed back in a 1:1 ratio to make sure both the tumor cells and immune cells are equally represented in the scRNA-seq dataset.Note: We recommend processing the single cell suspension with the GEM-X kit (10x), aiming for 1 × 104 target cells to ensure sufficient granularity in macrophage subsets. i.Sort live CD45+ and CD45− cells and collect in two separate Eppendorf tubes. Sort live CD45+ and CD45− cells and collect in two separate Eppendorf tubes. ii.Wash 1x with 1 mL PBS, spin at 300 g for 5 min and discard supernatant. Wash 1x with 1 mL PBS, spin at 300 g for 5 min and discard supernatant. iii.Resuspend cells in 0.04% BSA in PBS, mix CD45+ and CD45− cells in a 1:1 ratio (1000 cells per μL) and proceed to sequencing.Note: The CD45+ and CD45− cells are mixed back in a 1:1 ratio to make sure both the tumor cells and immune cells are equally represented in the scRNA-seq dataset.Note: We recommend processing the single cell suspension with the GEM-X kit (10x), aiming for 1 × 104 target cells to ensure sufficient granularity in macrophage subsets. Resuspend cells in 0.04% BSA in PBS, mix CD45+ and CD45− cells in a 1:1 ratio (1000 cells per μL) and proceed to sequencing.Note: The CD45+ and CD45− cells are mixed back in a 1:1 ratio to make sure both the tumor cells and immune cells are equally represented in the scRNA-seq dataset.Note: We recommend processing the single cell suspension with the GEM-X kit (10x), aiming for 1 × 104 target cells to ensure sufficient granularity in macrophage subsets. Note: The CD45+ and CD45− cells are mixed back in a 1:1 ratio to make sure both the tumor cells and immune cells are equally represented in the scRNA-seq dataset. Note: We recommend processing the single cell suspension with the GEM-X kit (10x), aiming for 1 × 104 target cells to ensure sufficient granularity in macrophage subsets. b.Bulk RNA sequencing or lipidomics downstream analysis on (non)-LLMs.i.Sort LLMs and non-LLMs according to the gating strategy depicted in Figure 2A. Process the collected cells, depending on the downstream analysis:ii.For lipidomics analyses, wash 1x with 1 mL PBS, spin at 300 g for 5 min and discard supernatant. Resuspend in 250 μL PBS, snap freeze on dry ice then store at −80°C.iii.For bulk RNA sequencing, homogenize 1–10 × 106 cells in 600 μL RLT lysis buffer; or 1 × 105–1 × 106 cells in 350 μL RLT lysis buffer; or 1 × 105 cells in 75 μL RLT lysis buffer. Store at −80°C. A minimum of 1 × 104 cells per population is recommended to ensure sufficient RNA for downstream analyses using Qiagen RNA Sequencing kits. Bulk RNA sequencing or lipidomics downstream analysis on (non)-LLMs.i.Sort LLMs and non-LLMs according to the gating strategy depicted in Figure 2A. Process the collected cells, depending on the downstream analysis:ii.For lipidomics analyses, wash 1x with 1 mL PBS, spin at 300 g for 5 min and discard supernatant. Resuspend in 250 μL PBS, snap freeze on dry ice then store at −80°C.iii.For bulk RNA sequencing, homogenize 1–10 × 106 cells in 600 μL RLT lysis buffer; or 1 × 105–1 × 106 cells in 350 μL RLT lysis buffer; or 1 × 105 cells in 75 μL RLT lysis buffer. Store at −80°C. A minimum of 1 × 104 cells per population is recommended to ensure sufficient RNA for downstream analyses using Qiagen RNA Sequencing kits. i.Sort LLMs and non-LLMs according to the gating strategy depicted in Figure 2A. Process the collected cells, depending on the downstream analysis: Sort LLMs and non-LLMs according to the gating strategy depicted in Figure 2A. Process the collected cells, depending on the downstream analysis: ii.For lipidomics analyses, wash 1x with 1 mL PBS, spin at 300 g for 5 min and discard supernatant. Resuspend in 250 μL PBS, snap freeze on dry ice then store at −80°C. For lipidomics analyses, wash 1x with 1 mL PBS, spin at 300 g for 5 min and discard supernatant. Resuspend in 250 μL PBS, snap freeze on dry ice then store at −80°C. iii.For bulk RNA sequencing, homogenize 1–10 × 106 cells in 600 μL RLT lysis buffer; or 1 × 105–1 × 106 cells in 350 μL RLT lysis buffer; or 1 × 105 cells in 75 μL RLT lysis buffer. Store at −80°C. A minimum of 1 × 104 cells per population is recommended to ensure sufficient RNA for downstream analyses using Qiagen RNA Sequencing kits. For bulk RNA sequencing, homogenize 1–10 × 106 cells in 600 μL RLT lysis buffer; or 1 × 105–1 × 106 cells in 350 μL RLT lysis buffer; or 1 × 105 cells in 75 μL RLT lysis buffer. Store at −80°C. A minimum of 1 × 104 cells per population is recommended to ensure sufficient RNA for downstream analyses using Qiagen RNA Sequencing kits. Representative flow cytometry gating strategy for analysis of the glioblastoma myeloid environment (A) Gating strategy for identification of lipid-laden macrophages (LLMs) in murine glioblastoma. Total cells were gated on forward and side scatter (FSC-A and SSC-A) to exclude debris. Single cells were isolated from total cells using the FSC-H and FSC-A to exclude doublets. Live cells were gated based on Zombie-NIR exclusion. Myeloid cell populations were gated based on CD11b expression within CD45 positive live cells. Tumor-associated macrophages (TAMs) were then gated as Ly6C− and Ly6G− cells and were separated into monocyte-derived macrophages (MDMs) and microglia (MG) based on CD49d expression (positive signal for MDMs and negative signal for MGs). LLMs can be identified for both TAM populations based on SSC-Ahigh and BODIPYhigh signal. (B) Gating strategy for identification of LLMs in murine HCC. All gates are similar to murine glioblastoma samples with the exception of separating tissue-resident macrophages, known as Kupffer cells, from MDMs in the total macrophage population. Kupffer cells were gated as CD11bintermediateF4-80high, whereas MDMs were gated as CD11bhighF4-80intermediate. Preparation and use of single-cell transcriptomic data to identify lipid source Timing: 1 h This section outlines the computational analysis steps leading towards the identification of mechanisms through which LLMs acquire a lipid-laden phenotype. By integrating the newly generated single cell RNA-seq dataset with the provided reference dataset, subsetting the LLM population and assessing their relative metabolic activity of several lipid pathways, new hypotheses can be generated in order to identify lipid sources driving the generation of LLMs (Figure 3). These steps are crucial for the design of downstream functional in vitro and ex vivo assays. 17.Load required packages (devtools v2.4.5, nichenetr v2.0.5, Seurat v5.1.0, data.table v1.15.4, scales v1.3.0, fmsb v0.7.6) and “reference_dataset.rds” into your current R workspace (version 4.1.1) using the following command. Load required packages (devtools v2.4.5, nichenetr v2.0.5, Seurat v5.1.0, data.table v1.15.4, scales v1.3.0, fmsb v0.7.6) and “reference_dataset.rds” into your current R workspace (version 4.1.1) using the following command. > if(!require(devtools)){ install.packages(“devtools”) > devtools::install_github(“saeyslab/nichenetr”) > install.packages(“Seurat”, “data.table”, “scales”, “fmsb”) > reference_dataset <- load("∼/reference_dataset.rds") # Use DietSeuarat to keep only RNA assay in reference_dataset.rds object. This makes the object smaller and reduces memory usage. > reference_dataset <- DietSeurat(reference_dataset, assays = "RNA") 18.Integrate your personal pre-processed single-cell RNA-seq Seurat object with the “reference_dataset”. Integrate your personal pre-processed single-cell RNA-seq Seurat object with the “reference_dataset”. > dataset <- load("location of object you which to analyze") > dataset <- DietSeurat(dataset, assays = "RNA") > dataset <- NormalizeData(dataset) # Use merge to combine the reference dataset with your own dataset > cancer.combined <- merge(reference_dataset, y = dataset, add.cell.ids = c("reference", "sample1"), project = "Kloosterman_et_al", merge.data = TRUE) 19.Label samples appropriately. Label samples appropriately. Note: For example, in reference dataset, glioblastoma and HCC models were used and annotated based on their genetic background: "Glioblastoma - PDG/p53KO”, “Glioblastoma - PDG/Ink4a-ArfKO” or “HCC – Nras12DOE/PtenKO”. Note: An example of how to annotate your sample is given below, replace “orig.ident_sample1” with the orig.ident and “label_sample1” with a relevant label for your sample. > cancer.combined$model <- plyr::mapvalues( x = cancer.combined$orig.ident, from = c("orig.ident_sample1”), to = c("label_sample1")) 20.Run this prompt to classify single cells as a macrophage based on common macrophage markers (macrophage module > 0). Subset the classified macrophages in a smaller dataset coined “cancer.tams.combined”. Run this prompt to classify single cells as a macrophage based on common macrophage markers (macrophage module > 0). Subset the classified macrophages in a smaller dataset coined “cancer.tams.combined”. # Use AddModuleScore to calculate the module score of the macrophage specific genes listed in this function > cancer.combined <- AddModuleScore(cancer.combined, features=list(c("Itga4", "Spi1", "Itgam", "Marco", "Trem2", "Csf1r")), name="Gene",nbin=100) >cancer.combined@meta.data[,paste("assignedto","Gene1", sep="")] <- "nonclassified" # Assign cells which module score is higher than 0 >cancer.combined@meta.data[which(cancer.combined@meta.data[,i]>0), paste(“assignedto","Gene1", sep="")] <- paste("assignedto","Gene1", sep=" ") > Idents(cancer.combined) new.cluster.ids <- c("Macrophages", "Rest") > names(new.cluster.ids) <- levels(cancer.combined) > cancer.combined <- RenameIdents(cancer.combined, new.cluster.ids) > cancer.combined$celltype <- Idents(cancer.combined) # Subset the cells classified as macrophages > cancer.tams.combined <- cancer.combined[, cancer.combined$celltype %in% c("Macrophages")] > rm(cancer.combined) 21.Run this prompt to label macrophages as LLMs (LLM module score > 0) or non-LLMs (LLM module score ≤ 0) using the LLM signature derived from Kloosterman and Erbani et al.1 Run this prompt to label macrophages as LLMs (LLM module score > 0) or non-LLMs (LLM module score ≤ 0) using the LLM signature derived from Kloosterman and Erbani et al.1 # Use AddModuleScore to calculate the module score of lipid-laden macrophage signature genes listed in this function > cancer.tams.combined <- AddModuleScore(cancer.tams.combined, features=list(c( "Gpnmb", "Spp1", "Fabp5", "Lgals3", "Arg1")), name="Gene",nbin=100) >cancer.tams.combined@meta.data[,paste("assignedto","Gene1", sep="")] <- "nonclassified" # Assign cells which module score is higher than 0 >cancer.tams.combined@meta.data[which(cancer.tams.combined@meta.data[,i]>0), paste("assignedto","Gene1", sep="")] <- paste("assignedto","Gene1", ,sep=" ") > Idents(cancer.tams.combined) <- cancer.tams.combined@meta.data$assignedtoGene1. # Classify the cells which module score is higher than 0 as “LLMs”, the cells 0 or lower as “non-LLMs” > new.cluster.ids <- c("non-LLMs", "LLMs") > names(new.cluster.ids) <- levels(cancer.tams.combined) > cancer.tams.combined <- RenameIdents(cancer.tams.combined, new.cluster.ids) > cancer.tams.combined$LLM <- Idents(cancer.tams.combined) 22.Generate lipid pathway gene signature (manually curated based on literature13,14,15) vectors in preparation for the gene signature enrichment analysis. Generate lipid pathway gene signature (manually curated based on literature13,14,15) vectors in preparation for the gene signature enrichment analysis. Optional: If you are interested in other lipid-related pathways, you may replace or add additional relevant transcriptional signatures. > lipid_uptake <- c("Cd36", "Marco", "Lrp8", "Vldlr", "Ldlr", "Olr1", "Scarb1", "Sra1", "Msr1") > phagocytosis <- c("C1qa", "C1qb", "C1qc", "Trem2", "Cd36") > cholesterol_biosynthesis <- c("Hmgcr", "Fdft1","Cyp51", "Dhcr24", "Dhcr7") > lipid_storage <- c("Plin5","Plin3","Plin2", "Plin1", "Apob", "Apoc4","Srebf2", "Nr1h2") > lipid_export <- c("Abca1", "Abca2","Abcg1", "Acat2", "Mttp", "Apoe") > pathway.list <- list(lipid_export, lipid_storage, cholesterol_biosynthesis, lipid_uptake, phagocytosis) 23.Run this prompt to generate an enrichment score for each pathway involved in lipid metabolism or lipid-laden macrophage formation (generated in previous step). Run this prompt to generate an enrichment score for each pathway involved in lipid metabolism or lipid-laden macrophage formation (generated in previous step). CRITICAL: Replace the “label_sample1” in “label_sample1 LLMs” with the relevant label you assigned to your sample at Step 19. > my_levels <- c("Glioblastoma - PDG/Ink4a LLMs”, "Glioblastoma - PDG/p53 LLMs”, “HCC - Nras12D/Pten LLMs”,"label_sample1 LLMs”) > fdscomplete <- c() # Use this prompt to calculate the module score of the previously defined metabolic pathways in LLMs from murine model > for (i in 1:5){ DefaultAssay(cancer.tams.combined) <- "RNA" Gene <- unlist(as.vector(pathway.list[[i]])) Gene <- Gene[Gene %in% rownames(cancer.tams.combined)] cancer.tams.combined <- AddModuleScore(cancer.tams.combined, features=list(c(Gene)), name="Gene",nbin=100) cancer.tams.combined.1 <- cancer.tams.combined [,cancer.tams.combined$LLMpermodel %in% c("Glioblastoma - PDG/Ink4a LLMs")] cancer.tams.combined.2 <- cancer.tams.combined [,cancer.tams.combined$LLMpermodel %in% c("Glioblastoma - PDG/p53 LLMs")] cancer.tams.combined.3 <- cancer.tams.combined [,cancer.tams.combined$LLMpermodel %in% c("HCC - Nras12D/Pten LLMs")] cancer.tams.combined.4 <- cancer.tams.combined [,cancer.tams.combined$LLMpermodel %in% c("sample1 LLMs")] df1 <- mean(cancer.tams.combined.1@meta.data$Gene) df2 <- mean(cancer.tams.combined.2@meta.data$Gene) df3 <- mean(cancer.tams.combined.3@meta.data$Gene) df4 <- mean(cancer.tams.combined.3@meta.data$Gene) fdscompared <- as.data.frame(cbind(df1, df2, df3, df4)) fdscompared <- t(fdscompared) row.names(fdscompared) <- my_levels fdscomplete <- cbind(fdscomplete, fdscompared) rm(fdscores) } 24.Create a radar plot to visualize the relative pathway activity. Create a radar plot to visualize the relative pathway activity. CRITICAL: If you adjusted the gene signatures at Step 22, make sure to adjust the titles of the plots accordingly in line 1. CRITICAL: This prompt is written for the analysis of the reference dataset and one additional condition (“label_sample1”). To add more than one condition, replace the “1:4” statement in line 2 with “1:5” for 2 additional samples, with “1:6” for 3 additional samples, and in line 12 with “3:7” or “3:8” respectively. > colnames(fdscomplete) <- c("Lipid export", "Lipid storage", "Cholesterol biosynthesis", "Lipid uptake", "Phagocytosis") > df_scaled <- round(apply(fdscomplete[c(1:4),], 2, scales::rescale), 2) > df_scaled <- as.data.frame(df_scaled) > col_max <- apply(df_scaled, 2, max) > col_min <- apply(df_scaled, 2, min) > col_mean <- apply(df_scaled, 2, mean) > col_summary <- t(data.frame(Max = col_max, Min = col_min, Average = col_mean)) > df_scaled2 <- as.data.frame(rbind(col_summary, df_scaled)) > opar <- par() > par(mar = rep(0.8,4)) > par(mfrow = c(1,6)) # Use this prompt to create the radar plot > for (i in 3:6) { radarchart( df_scaled2[c(1:3, i), ], pfcol = c("#99999980",NA), pcol= c(NA,2), plty = 1, plwd = 2, title = row.names(df_scaled2)[i] )} > par <- par(opar) A three-step workflow to assess relative lipid-pathway activity in LLMs from single-cell RNA-seq dataset (A) Computational workflow to: 1) integrate the single-cell RNA-seq dataset obtained from Step 16a with the provided reference dataset containing single-cell RNA-seq data from glioblastoma- and HCC-derived LLMs; 2) subset the LLM population by labeling cells based on the LLM signature; and 3) assess the relative activity of various lipid-pathways in LLMs to identify the potential source of lipids. (B) Uniform Manifold Approximation and Projection (UMAP) representation of integrated glioblastoma and HCC datasets after labeling cells as macrophage or non-macrophages using a pan-macrophage signature (macrophage > 0). (C) UMAP representation of macrophage subset from (B), cells are labeled as LLM or non-LLM based on LLM signature enrichment score (LLM > 0). (D) Representative radar plot depicting enrichment scores in LLMs. For each model, a radar plot is generated with their relative metabolic activity compared to other models (purple dots), as the gray area depict the average metabolic activity across all samples. This explains the need for a reference dataset, and results should thus be interpreted as relative, not absolute, values. Preparation of primary bone-marrow derived macrophages (BMDMs) Timing: 2 h This section describes how to generate BMDMs for functional in vitro and ex vivo assays as shown in Figure 4. 25.Sacrifice mouse in a biosafety cabinet according to the institutional and ethical guidelines, for instance using the following methods:CRITICAL: Work in a sterile flow cabinet for each step to prevent contamination of the BMDMs during the experiment.a.Inject mice with Avertin (0.8 mL per mouse is recommended).b.Cervical dislocation.c.CO2 overdose.Note: Mice from different genetic backgrounds can be used depending on experimental questions (i.e. Gt(ROSA)26Sortm4(ACTB-tdTomato,-EGFP)Luo/J (C57BL/6J background; named dTomato hereafter) for tracing experiments or LysM-Cre Abca1/Abcg1fl/fl (C57BL/6J background)16 for functional assays as described in Kloosterman, Erbani et al.1). Sacrifice mouse in a biosafety cabinet according to the institutional and ethical guidelines, for instance using the following methods:CRITICAL: Work in a sterile flow cabinet for each step to prevent contamination of the BMDMs during the experiment.a.Inject mice with Avertin (0.8 mL per mouse is recommended).b.Cervical dislocation.c.CO2 overdose.Note: Mice from different genetic backgrounds can be used depending on experimental questions (i.e. Gt(ROSA)26Sortm4(ACTB-tdTomato,-EGFP)Luo/J (C57BL/6J background; named dTomato hereafter) for tracing experiments or LysM-Cre Abca1/Abcg1fl/fl (C57BL/6J background)16 for functional assays as described in Kloosterman, Erbani et al.1). CRITICAL: Work in a sterile flow cabinet for each step to prevent contamination of the BMDMs during the experiment. a.Inject mice with Avertin (0.8 mL per mouse is recommended). Inject mice with Avertin (0.8 mL per mouse is recommended). b.Cervical dislocation. Cervical dislocation. c.CO2 overdose.Note: Mice from different genetic backgrounds can be used depending on experimental questions (i.e. Gt(ROSA)26Sortm4(ACTB-tdTomato,-EGFP)Luo/J (C57BL/6J background; named dTomato hereafter) for tracing experiments or LysM-Cre Abca1/Abcg1fl/fl (C57BL/6J background)16 for functional assays as described in Kloosterman, Erbani et al.1). CO2 overdose.Note: Mice from different genetic backgrounds can be used depending on experimental questions (i.e. Gt(ROSA)26Sortm4(ACTB-tdTomato,-EGFP)Luo/J (C57BL/6J background; named dTomato hereafter) for tracing experiments or LysM-Cre Abca1/Abcg1fl/fl (C57BL/6J background)16 for functional assays as described in Kloosterman, Erbani et al.1). Note: Mice from different genetic backgrounds can be used depending on experimental questions (i.e. Gt(ROSA)26Sortm4(ACTB-tdTomato,-EGFP)Luo/J (C57BL/6J background; named dTomato hereafter) for tracing experiments or LysM-Cre Abca1/Abcg1fl/fl (C57BL/6J background)16 for functional assays as described in Kloosterman, Erbani et al.1). 26.Collect the femurs and tibiae.a.Dissect the skin/fur from the abdomen and hind legs.b.Remove both legs from the mouse including the hip bone, femur and tibiae.c.Place legs in cold maintenance media on ice (Figure 4A). Collect the femurs and tibiae.a.Dissect the skin/fur from the abdomen and hind legs.b.Remove both legs from the mouse including the hip bone, femur and tibiae.c.Place legs in cold maintenance media on ice (Figure 4A). a.Dissect the skin/fur from the abdomen and hind legs. Dissect the skin/fur from the abdomen and hind legs. b.Remove both legs from the mouse including the hip bone, femur and tibiae. Remove both legs from the mouse including the hip bone, femur and tibiae. c.Place legs in cold maintenance media on ice (Figure 4A). Place legs in cold maintenance media on ice (Figure 4A). Note: Pay attention not to break the bones while collecting them, as this may compromise the sterility of the bone marrow cells. 27.Flush the femurs and tibiae.a.Remove all muscles from the legs using a disposable scalpel or scissors (Figure 4B).b.Separate the femur and tibiae.c.Cut off a small piece of bone at both ends of the femur and tibiae and flush with 10 mL cold maintenance media using a 10 mL syringe with a 251/2G needle (Figure 4C). Flush the femurs and tibiae.a.Remove all muscles from the legs using a disposable scalpel or scissors (Figure 4B).b.Separate the femur and tibiae.c.Cut off a small piece of bone at both ends of the femur and tibiae and flush with 10 mL cold maintenance media using a 10 mL syringe with a 251/2G needle (Figure 4C). a.Remove all muscles from the legs using a disposable scalpel or scissors (Figure 4B). Remove all muscles from the legs using a disposable scalpel or scissors (Figure 4B). b.Separate the femur and tibiae. Separate the femur and tibiae. c.Cut off a small piece of bone at both ends of the femur and tibiae and flush with 10 mL cold maintenance media using a 10 mL syringe with a 251/2G needle (Figure 4C). Cut off a small piece of bone at both ends of the femur and tibiae and flush with 10 mL cold maintenance media using a 10 mL syringe with a 251/2G needle (Figure 4C). 28.Transfer bone marrow cell suspension to Teflon bag.a.Pass the collected bone-marrow cell suspension through a 70 μm strainer.b.Spin down at 300 g for 5 min at 4°C.c.Aspirate supernatant and resuspend in 30 mL maintenance media + 10 ng/mL CSF-1.d.Transfer cells to 30 mL Teflon bag using a 10 mL pipette and place in a 37°C incubator for 5 days, changing media every other day with fresh maintenance media + 10 ng/mL CSF-1 (Figure 4D). Transfer bone marrow cell suspension to Teflon bag.a.Pass the collected bone-marrow cell suspension through a 70 μm strainer.b.Spin down at 300 g for 5 min at 4°C.c.Aspirate supernatant and resuspend in 30 mL maintenance media + 10 ng/mL CSF-1.d.Transfer cells to 30 mL Teflon bag using a 10 mL pipette and place in a 37°C incubator for 5 days, changing media every other day with fresh maintenance media + 10 ng/mL CSF-1 (Figure 4D). a.Pass the collected bone-marrow cell suspension through a 70 μm strainer. Pass the collected bone-marrow cell suspension through a 70 μm strainer. b.Spin down at 300 g for 5 min at 4°C. Spin down at 300 g for 5 min at 4°C. c.Aspirate supernatant and resuspend in 30 mL maintenance media + 10 ng/mL CSF-1. Aspirate supernatant and resuspend in 30 mL maintenance media + 10 ng/mL CSF-1. d.Transfer cells to 30 mL Teflon bag using a 10 mL pipette and place in a 37°C incubator for 5 days, changing media every other day with fresh maintenance media + 10 ng/mL CSF-1 (Figure 4D). Transfer cells to 30 mL Teflon bag using a 10 mL pipette and place in a 37°C incubator for 5 days, changing media every other day with fresh maintenance media + 10 ng/mL CSF-1 (Figure 4D). Note: Culturing in Teflon bags is essential to maintain bone marrow cells in suspension during differentiation, as the material from these bags prevents them from attaching and maintain a more unbiased activation state compared to plate cultures.17 Once the cells have differentiated into BMDMs after 5 days, they can be taken out of the bag (as outlined below), counted and plated for experiment without the need to trypsinize, which can be harmful for BMDMs. BMDMs cultured in Teflon bags experience less stress during washes or transfers, and can be expanded in larger volumes, compared to BMDMs grown on non-tissue cultured plates. Note: To transfer BMDMs out of the Teflon bags and refresh media, gently tap the bag to detach any BMDMs attached to the lining of the bag. Empty the content of the bag using a 10 mL pipette and transfer to a 50 mL falcon tube. Spin down at 300 g for 5 min at 4°C, discard supernatant, and resuspend in 30 mL maintenance media + 10 ng/mL CSF-1. Transfer back to the Teflon bag with a 10 mL pipette. Preparation and culturing of BMDMs in Teflon bags (A) Dissect the skin/fur from the hind legs and remove both legs including the hip bone, femur and tibiae. Avoid breaking the bones. (B) Remove all muscle tissues from the bones using a scissor (or scalpel). (C) Separate the femur and tibiae and cut off a small piece of bone from both ends and flush it with a 251/2G needle through a 40 μm cell strainer. (D) Wash the bone-marrow cell suspension and resuspend in 30 mL of maintenance media supplemented with 10 ng/mL CSF-1 before transferring the cells to a Teflon bag with a 10 mL pipette. In vitro LLM formation assay Timing: day 1: 4 h; day 2: 2 h; day 3: 3 h; day 4: 4 h After the computational analysis of the single-cell RNA sequencing dataset (Steps 17 to 24), aimed at identifying a potential source of lipids, we next outline steps to validate these newly generated hypotheses using an in vitro LLM formation assay. 29.Generate tumor-conditioned media (TCM) from chosen tumor cell line and tumor cell collection.Note: Instructions on how to generate cell lines from primary murine tumors are described in Step 8a. In vitro experiments should be performed when the cell lines are in a phase of exponential growth.a.Aspirate the media from a full (sub-confluent, approximately between 2–6×106 tumor cells, depending on the cell line) T175 tumor cell line flask.b.Rinse the cells with PBS, afterwards remove PBS with aspiration.c.Add 5 mL Trypsin, incubate at 37°C for 2–15 min.d.Harvest the tumor cells by resuspending the detached cells in 5 mL 10% FCS DMEM.e.Transfer the cells to a 15 mL tube, spin down at 300 g for 5 min, resuspend in 5 mL of maintenance media and count.f.Plate 2 × 106 tumor cells in 12 mL maintenance media (see materials and equipment section) in a T75 flask.g.Once tumor cells have attached, refresh media with 13 mL low-serum media (see materials and equipment section) and incubate at 37°C overnight.CRITICAL: The amount of time needed for tumor cells to attach to the plate depends on the cell line and can take approximately 2–4 h. Always check that the cells have fully attached before refreshing the media.h.Transfer the supernatant to a 15 mL tube, spin down at 300 g for 5 min.i.Transfer the supernatant to a Amicon Ultra-15 Centrifugal Filter Unit. Spin down at 4500 g for 45 min at 4°C.j.Collect the concentrate from the top of the filter (around 200 μL) and mix with 13 mL of maintenance media to generate TCM. Generate tumor-conditioned media (TCM) from chosen tumor cell line and tumor cell collection.Note: Instructions on how to generate cell lines from primary murine tumors are described in Step 8a. In vitro experiments should be performed when the cell lines are in a phase of exponential growth.a.Aspirate the media from a full (sub-confluent, approximately between 2–6×106 tumor cells, depending on the cell line) T175 tumor cell line flask.b.Rinse the cells with PBS, afterwards remove PBS with aspiration.c.Add 5 mL Trypsin, incubate at 37°C for 2–15 min.d.Harvest the tumor cells by resuspending the detached cells in 5 mL 10% FCS DMEM.e.Transfer the cells to a 15 mL tube, spin down at 300 g for 5 min, resuspend in 5 mL of maintenance media and count.f.Plate 2 × 106 tumor cells in 12 mL maintenance media (see materials and equipment section) in a T75 flask.g.Once tumor cells have attached, refresh media with 13 mL low-serum media (see materials and equipment section) and incubate at 37°C overnight.CRITICAL: The amount of time needed for tumor cells to attach to the plate depends on the cell line and can take approximately 2–4 h. Always check that the cells have fully attached before refreshing the media.h.Transfer the supernatant to a 15 mL tube, spin down at 300 g for 5 min.i.Transfer the supernatant to a Amicon Ultra-15 Centrifugal Filter Unit. Spin down at 4500 g for 45 min at 4°C.j.Collect the concentrate from the top of the filter (around 200 μL) and mix with 13 mL of maintenance media to generate TCM. Note: Instructions on how to generate cell lines from primary murine tumors are described in Step 8a. In vitro experiments should be performed when the cell lines are in a phase of exponential growth. a.Aspirate the media from a full (sub-confluent, approximately between 2–6×106 tumor cells, depending on the cell line) T175 tumor cell line flask. Aspirate the media from a full (sub-confluent, approximately between 2–6×106 tumor cells, depending on the cell line) T175 tumor cell line flask. b.Rinse the cells with PBS, afterwards remove PBS with aspiration. Rinse the cells with PBS, afterwards remove PBS with aspiration. c.Add 5 mL Trypsin, incubate at 37°C for 2–15 min. Add 5 mL Trypsin, incubate at 37°C for 2–15 min. d.Harvest the tumor cells by resuspending the detached cells in 5 mL 10% FCS DMEM. Harvest the tumor cells by resuspending the detached cells in 5 mL 10% FCS DMEM. e.Transfer the cells to a 15 mL tube, spin down at 300 g for 5 min, resuspend in 5 mL of maintenance media and count. Transfer the cells to a 15 mL tube, spin down at 300 g for 5 min, resuspend in 5 mL of maintenance media and count. f.Plate 2 × 106 tumor cells in 12 mL maintenance media (see materials and equipment section) in a T75 flask. Plate 2 × 106 tumor cells in 12 mL maintenance media (see materials and equipment section) in a T75 flask. g.Once tumor cells have attached, refresh media with 13 mL low-serum media (see materials and equipment section) and incubate at 37°C overnight.CRITICAL: The amount of time needed for tumor cells to attach to the plate depends on the cell line and can take approximately 2–4 h. Always check that the cells have fully attached before refreshing the media. Once tumor cells have attached, refresh media with 13 mL low-serum media (see materials and equipment section) and incubate at 37°C overnight.CRITICAL: The amount of time needed for tumor cells to attach to the plate depends on the cell line and can take approximately 2–4 h. Always check that the cells have fully attached before refreshing the media. CRITICAL: The amount of time needed for tumor cells to attach to the plate depends on the cell line and can take approximately 2–4 h. Always check that the cells have fully attached before refreshing the media. h.Transfer the supernatant to a 15 mL tube, spin down at 300 g for 5 min. Transfer the supernatant to a 15 mL tube, spin down at 300 g for 5 min. i.Transfer the supernatant to a Amicon Ultra-15 Centrifugal Filter Unit. Spin down at 4500 g for 45 min at 4°C. Transfer the supernatant to a Amicon Ultra-15 Centrifugal Filter Unit. Spin down at 4500 g for 45 min at 4°C. j.Collect the concentrate from the top of the filter (around 200 μL) and mix with 13 mL of maintenance media to generate TCM. Collect the concentrate from the top of the filter (around 200 μL) and mix with 13 mL of maintenance media to generate TCM. 30.Coat 6-well plates with Poly-D-Lysine (PDL).a.Add 1 mL of PDL to each well.b.Incubate at 37°C for 1 h.c.Transfer the residual PDL back into an empty 50 mL tube for storage (PDL can be re-used multiple times to coat wells).d.Wash away residual PDL with 2 mL of PBS.e.Add another 2 mL of PBS to the wells until use, to prevent the wells from drying out. Coat 6-well plates with Poly-D-Lysine (PDL).a.Add 1 mL of PDL to each well.b.Incubate at 37°C for 1 h.c.Transfer the residual PDL back into an empty 50 mL tube for storage (PDL can be re-used multiple times to coat wells).d.Wash away residual PDL with 2 mL of PBS.e.Add another 2 mL of PBS to the wells until use, to prevent the wells from drying out. a.Add 1 mL of PDL to each well. Add 1 mL of PDL to each well. b.Incubate at 37°C for 1 h. Incubate at 37°C for 1 h. c.Transfer the residual PDL back into an empty 50 mL tube for storage (PDL can be re-used multiple times to coat wells). Transfer the residual PDL back into an empty 50 mL tube for storage (PDL can be re-used multiple times to coat wells). d.Wash away residual PDL with 2 mL of PBS. Wash away residual PDL with 2 mL of PBS. e.Add another 2 mL of PBS to the wells until use, to prevent the wells from drying out. Add another 2 mL of PBS to the wells until use, to prevent the wells from drying out. Optional: PDL-coated 6-well plates can be prepared in advance and wrapped in parafilm before storage at 4°C for up to 2 weeks. 31.Plate the BMDMs onto PDL-coated plates.a.Transfer the BMDMs from Teflon bags (see Steps 25 to 28 for instructions on generating primary BMDMs) to a 50 mL tube and count.b.Transfer 1.5 × 106 BMDMs to a 15 mL tube for each condition, either non-educated or TCM-educated.Note: 3 × 105 BMDMs per well of a 6-well plate should be plated. In general, we recommend two technical replicates per biological replicate, thus 6 × 105 BMDMs are needed per condition. This experiment aims to assess LLM formation from BMDMs exposed to lipids or not, previously educated in TCM or not: 4 conditions per experiment in total. Thus 4 × 6 × 105 = 2.4 × 106 BMDMs needed in total; allowing for excess, 3 × 106 cells are prepared and divided over two 15 mL tubes (each to be resuspended in either TCM or control media).c.Spin down at 300 g for 5 min at 4°C.d.Resuspend BMDM pellets in 10 mL maintenance media + 10 ng/mL CSF-1 or TCM + 10 ng/mL CSF-1.e.Transfer 2 mL of the BMDM (3 × 105) solution to each well.f.Incubate at 37°C for 20 h.Optional: It is possible to add pharmacological inhibitors at this step, aiming to interfere with the accumulation or uptake of lipids in macrophages. For example, add 200 μM sulfo-N-succinimidyl oleate (SSO), an inhibitor of lipid receptor CD36, to assess the importance of CD36 on the acquisition of a lipid-laden phenotype. Plate the BMDMs onto PDL-coated plates.a.Transfer the BMDMs from Teflon bags (see Steps 25 to 28 for instructions on generating primary BMDMs) to a 50 mL tube and count.b.Transfer 1.5 × 106 BMDMs to a 15 mL tube for each condition, either non-educated or TCM-educated.Note: 3 × 105 BMDMs per well of a 6-well plate should be plated. In general, we recommend two technical replicates per biological replicate, thus 6 × 105 BMDMs are needed per condition. This experiment aims to assess LLM formation from BMDMs exposed to lipids or not, previously educated in TCM or not: 4 conditions per experiment in total. Thus 4 × 6 × 105 = 2.4 × 106 BMDMs needed in total; allowing for excess, 3 × 106 cells are prepared and divided over two 15 mL tubes (each to be resuspended in either TCM or control media).c.Spin down at 300 g for 5 min at 4°C.d.Resuspend BMDM pellets in 10 mL maintenance media + 10 ng/mL CSF-1 or TCM + 10 ng/mL CSF-1.e.Transfer 2 mL of the BMDM (3 × 105) solution to each well.f.Incubate at 37°C for 20 h.Optional: It is possible to add pharmacological inhibitors at this step, aiming to interfere with the accumulation or uptake of lipids in macrophages. For example, add 200 μM sulfo-N-succinimidyl oleate (SSO), an inhibitor of lipid receptor CD36, to assess the importance of CD36 on the acquisition of a lipid-laden phenotype. a.Transfer the BMDMs from Teflon bags (see Steps 25 to 28 for instructions on generating primary BMDMs) to a 50 mL tube and count. Transfer the BMDMs from Teflon bags (see Steps 25 to 28 for instructions on generating primary BMDMs) to a 50 mL tube and count. b.Transfer 1.5 × 106 BMDMs to a 15 mL tube for each condition, either non-educated or TCM-educated.Note: 3 × 105 BMDMs per well of a 6-well plate should be plated. In general, we recommend two technical replicates per biological replicate, thus 6 × 105 BMDMs are needed per condition. This experiment aims to assess LLM formation from BMDMs exposed to lipids or not, previously educated in TCM or not: 4 conditions per experiment in total. Thus 4 × 6 × 105 = 2.4 × 106 BMDMs needed in total; allowing for excess, 3 × 106 cells are prepared and divided over two 15 mL tubes (each to be resuspended in either TCM or control media). Transfer 1.5 × 106 BMDMs to a 15 mL tube for each condition, either non-educated or TCM-educated.Note: 3 × 105 BMDMs per well of a 6-well plate should be plated. In general, we recommend two technical replicates per biological replicate, thus 6 × 105 BMDMs are needed per condition. This experiment aims to assess LLM formation from BMDMs exposed to lipids or not, previously educated in TCM or not: 4 conditions per experiment in total. Thus 4 × 6 × 105 = 2.4 × 106 BMDMs needed in total; allowing for excess, 3 × 106 cells are prepared and divided over two 15 mL tubes (each to be resuspended in either TCM or control media). Note: 3 × 105 BMDMs per well of a 6-well plate should be plated. In general, we recommend two technical replicates per biological replicate, thus 6 × 105 BMDMs are needed per condition. This experiment aims to assess LLM formation from BMDMs exposed to lipids or not, previously educated in TCM or not: 4 conditions per experiment in total. Thus 4 × 6 × 105 = 2.4 × 106 BMDMs needed in total; allowing for excess, 3 × 106 cells are prepared and divided over two 15 mL tubes (each to be resuspended in either TCM or control media). c.Spin down at 300 g for 5 min at 4°C. Spin down at 300 g for 5 min at 4°C. d.Resuspend BMDM pellets in 10 mL maintenance media + 10 ng/mL CSF-1 or TCM + 10 ng/mL CSF-1. Resuspend BMDM pellets in 10 mL maintenance media + 10 ng/mL CSF-1 or TCM + 10 ng/mL CSF-1. e.Transfer 2 mL of the BMDM (3 × 105) solution to each well. Transfer 2 mL of the BMDM (3 × 105) solution to each well. f.Incubate at 37°C for 20 h.Optional: It is possible to add pharmacological inhibitors at this step, aiming to interfere with the accumulation or uptake of lipids in macrophages. For example, add 200 μM sulfo-N-succinimidyl oleate (SSO), an inhibitor of lipid receptor CD36, to assess the importance of CD36 on the acquisition of a lipid-laden phenotype. Incubate at 37°C for 20 h.Optional: It is possible to add pharmacological inhibitors at this step, aiming to interfere with the accumulation or uptake of lipids in macrophages. For example, add 200 μM sulfo-N-succinimidyl oleate (SSO), an inhibitor of lipid receptor CD36, to assess the importance of CD36 on the acquisition of a lipid-laden phenotype. Optional: It is possible to add pharmacological inhibitors at this step, aiming to interfere with the accumulation or uptake of lipids in macrophages. For example, add 200 μM sulfo-N-succinimidyl oleate (SSO), an inhibitor of lipid receptor CD36, to assess the importance of CD36 on the acquisition of a lipid-laden phenotype. 32.Challenge BMDMs with external lipid source.a.Remove maintenance media or tumor-conditioned media from the wells and collect into two 15 mL tubes.b.Add 2 mL maintenance media +10 ng/mL CSF-1 in all wells.c.Add myelin debris (1 mg/mL) or other lipids for 3 h.Alternative: The hypothetical source of lipids will be determined previously during Step 24. In the context of glioblastoma, myelin debris isolated from healthy brain was used as the source of lipids to generate lipid-laden macrophages.18 However, in other types of cancer the source of lipids driving LLM formation will likely differ. Based on the hypothesis generated in Step 24, the candidate lipid source should be titrated to determine the concentration and duration of exposure that are optimal for this lipid challenge.Note: Different lipid sources can be tested in parallel to assess the most potent inducer of macrophages’ lipid-laden phenotype. A potent LLM induction is determined based on increased granularity as well as lipid content.d.Aspirate media from each well and re-add the 2 mL of media collected at Step 32a to the respective well.e.Incubate at 37°C for 24 h. Challenge BMDMs with external lipid source.a.Remove maintenance media or tumor-conditioned media from the wells and collect into two 15 mL tubes.b.Add 2 mL maintenance media +10 ng/mL CSF-1 in all wells.c.Add myelin debris (1 mg/mL) or other lipids for 3 h.Alternative: The hypothetical source of lipids will be determined previously during Step 24. In the context of glioblastoma, myelin debris isolated from healthy brain was used as the source of lipids to generate lipid-laden macrophages.18 However, in other types of cancer the source of lipids driving LLM formation will likely differ. Based on the hypothesis generated in Step 24, the candidate lipid source should be titrated to determine the concentration and duration of exposure that are optimal for this lipid challenge.Note: Different lipid sources can be tested in parallel to assess the most potent inducer of macrophages’ lipid-laden phenotype. A potent LLM induction is determined based on increased granularity as well as lipid content.d.Aspirate media from each well and re-add the 2 mL of media collected at Step 32a to the respective well.e.Incubate at 37°C for 24 h. a.Remove maintenance media or tumor-conditioned media from the wells and collect into two 15 mL tubes. Remove maintenance media or tumor-conditioned media from the wells and collect into two 15 mL tubes. b.Add 2 mL maintenance media +10 ng/mL CSF-1 in all wells. Add 2 mL maintenance media +10 ng/mL CSF-1 in all wells. c.Add myelin debris (1 mg/mL) or other lipids for 3 h.Alternative: The hypothetical source of lipids will be determined previously during Step 24. In the context of glioblastoma, myelin debris isolated from healthy brain was used as the source of lipids to generate lipid-laden macrophages.18 However, in other types of cancer the source of lipids driving LLM formation will likely differ. Based on the hypothesis generated in Step 24, the candidate lipid source should be titrated to determine the concentration and duration of exposure that are optimal for this lipid challenge.Note: Different lipid sources can be tested in parallel to assess the most potent inducer of macrophages’ lipid-laden phenotype. A potent LLM induction is determined based on increased granularity as well as lipid content. Add myelin debris (1 mg/mL) or other lipids for 3 h.Alternative: The hypothetical source of lipids will be determined previously during Step 24. In the context of glioblastoma, myelin debris isolated from healthy brain was used as the source of lipids to generate lipid-laden macrophages.18 However, in other types of cancer the source of lipids driving LLM formation will likely differ. Based on the hypothesis generated in Step 24, the candidate lipid source should be titrated to determine the concentration and duration of exposure that are optimal for this lipid challenge.Note: Different lipid sources can be tested in parallel to assess the most potent inducer of macrophages’ lipid-laden phenotype. A potent LLM induction is determined based on increased granularity as well as lipid content. Alternative: The hypothetical source of lipids will be determined previously during Step 24. In the context of glioblastoma, myelin debris isolated from healthy brain was used as the source of lipids to generate lipid-laden macrophages.18 However, in other types of cancer the source of lipids driving LLM formation will likely differ. Based on the hypothesis generated in Step 24, the candidate lipid source should be titrated to determine the concentration and duration of exposure that are optimal for this lipid challenge. Note: Different lipid sources can be tested in parallel to assess the most potent inducer of macrophages’ lipid-laden phenotype. A potent LLM induction is determined based on increased granularity as well as lipid content. d.Aspirate media from each well and re-add the 2 mL of media collected at Step 32a to the respective well. Aspirate media from each well and re-add the 2 mL of media collected at Step 32a to the respective well. e.Incubate at 37°C for 24 h. Incubate at 37°C for 24 h. 33.Harvest the BMDMs for experimental readout.a.Aspirate media.b.Wash cells 1x with PBS to remove remaining medium.c.Add 500 μL trypsin per well, place in 37°C incubator for 10 min.d.Check under the microscope that most cells have detached.e.Inhibit trypsin with 500 μL of maintenance medium in each well.f.Use a p1000 tip to scrape off BMDMs that remained attached.g.Flush the wells to detach any remaining BMDMs and transfer to 1.5 mL Eppendorf tube.h.Spin down at 300 g for 5 min.i.Remove supernatant, leaving around 100 μL, and resuspend pellet. Harvest the BMDMs for experimental readout.a.Aspirate media.b.Wash cells 1x with PBS to remove remaining medium.c.Add 500 μL trypsin per well, place in 37°C incubator for 10 min.d.Check under the microscope that most cells have detached.e.Inhibit trypsin with 500 μL of maintenance medium in each well.f.Use a p1000 tip to scrape off BMDMs that remained attached.g.Flush the wells to detach any remaining BMDMs and transfer to 1.5 mL Eppendorf tube.h.Spin down at 300 g for 5 min.i.Remove supernatant, leaving around 100 μL, and resuspend pellet. a.Aspirate media. Aspirate media. b.Wash cells 1x with PBS to remove remaining medium. Wash cells 1x with PBS to remove remaining medium. c.Add 500 μL trypsin per well, place in 37°C incubator for 10 min. Add 500 μL trypsin per well, place in 37°C incubator for 10 min. d.Check under the microscope that most cells have detached. Check under the microscope that most cells have detached. e.Inhibit trypsin with 500 μL of maintenance medium in each well. Inhibit trypsin with 500 μL of maintenance medium in each well. f.Use a p1000 tip to scrape off BMDMs that remained attached. Use a p1000 tip to scrape off BMDMs that remained attached. g.Flush the wells to detach any remaining BMDMs and transfer to 1.5 mL Eppendorf tube. Flush the wells to detach any remaining BMDMs and transfer to 1.5 mL Eppendorf tube. h.Spin down at 300 g for 5 min. Spin down at 300 g for 5 min. i.Remove supernatant, leaving around 100 μL, and resuspend pellet. Remove supernatant, leaving around 100 μL, and resuspend pellet. 34.Transfer single cell suspension to 96-well plate (round bottom) to proceed with flow cytometry staining.CRITICAL: Split single cell suspension into multiple wells for compensation control samples that require cells (i.e. unstained, live/dead and BODIPY compensation samples).a.Spin down plate at 550 g for 2 min and remove supernatant by inverting plate and tapping it dry on a paper towel.b.Wash 1x by adding 200 μL of FB to each well, spin down and remove supernatant as described above in 34a. Transfer single cell suspension to 96-well plate (round bottom) to proceed with flow cytometry staining.CRITICAL: Split single cell suspension into multiple wells for compensation control samples that require cells (i.e. unstained, live/dead and BODIPY compensation samples).a.Spin down plate at 550 g for 2 min and remove supernatant by inverting plate and tapping it dry on a paper towel.b.Wash 1x by adding 200 μL of FB to each well, spin down and remove supernatant as described above in 34a. CRITICAL: Split single cell suspension into multiple wells for compensation control samples that require cells (i.e. unstained, live/dead and BODIPY compensation samples). a.Spin down plate at 550 g for 2 min and remove supernatant by inverting plate and tapping it dry on a paper towel. Spin down plate at 550 g for 2 min and remove supernatant by inverting plate and tapping it dry on a paper towel. b.Wash 1x by adding 200 μL of FB to each well, spin down and remove supernatant as described above in 34a. Wash 1x by adding 200 μL of FB to each well, spin down and remove supernatant as described above in 34a. 35.Sample blocking and antibody staining.a.Resuspend cells in 50 μL blocking buffer (see materials and equipment section) and incubate for 15–30 min on ice.b.Spin down plate at 550 g for 2 min and remove supernatant.c.Add 50 μL of antibody mix 5 (see materials and equipment section) and incubate for 30 min on ice protected from light.CRITICAL: For live/dead compensation sample add 100 μL fixation solution (see materials and equipment section) instead of antibody mix 5 during staining process.d.Centrifuge plate at 550 g for 2 min and remove supernatant, wash 1x in FB and 1x in PBS.Note: It is important to wash cells in PBS prior to live/dead staining to remove any traces of serum. Sample blocking and antibody staining.a.Resuspend cells in 50 μL blocking buffer (see materials and equipment section) and incubate for 15–30 min on ice.b.Spin down plate at 550 g for 2 min and remove supernatant.c.Add 50 μL of antibody mix 5 (see materials and equipment section) and incubate for 30 min on ice protected from light.CRITICAL: For live/dead compensation sample add 100 μL fixation solution (see materials and equipment section) instead of antibody mix 5 during staining process.d.Centrifuge plate at 550 g for 2 min and remove supernatant, wash 1x in FB and 1x in PBS.Note: It is important to wash cells in PBS prior to live/dead staining to remove any traces of serum. a.Resuspend cells in 50 μL blocking buffer (see materials and equipment section) and incubate for 15–30 min on ice. Resuspend cells in 50 μL blocking buffer (see materials and equipment section) and incubate for 15–30 min on ice. b.Spin down plate at 550 g for 2 min and remove supernatant. Spin down plate at 550 g for 2 min and remove supernatant. c.Add 50 μL of antibody mix 5 (see materials and equipment section) and incubate for 30 min on ice protected from light.CRITICAL: For live/dead compensation sample add 100 μL fixation solution (see materials and equipment section) instead of antibody mix 5 during staining process. Add 50 μL of antibody mix 5 (see materials and equipment section) and incubate for 30 min on ice protected from light.CRITICAL: For live/dead compensation sample add 100 μL fixation solution (see materials and equipment section) instead of antibody mix 5 during staining process. CRITICAL: For live/dead compensation sample add 100 μL fixation solution (see materials and equipment section) instead of antibody mix 5 during staining process. d.Centrifuge plate at 550 g for 2 min and remove supernatant, wash 1x in FB and 1x in PBS.Note: It is important to wash cells in PBS prior to live/dead staining to remove any traces of serum. Centrifuge plate at 550 g for 2 min and remove supernatant, wash 1x in FB and 1x in PBS.Note: It is important to wash cells in PBS prior to live/dead staining to remove any traces of serum. Note: It is important to wash cells in PBS prior to live/dead staining to remove any traces of serum. 36.Live/dead staining.a.Prepare Zombie NIR live/dead staining solution in PBS (see materials and equipment section).b.Add 50 μL of staining solution to cells. Resuspend and incubate for 30 min on ice protected from light.Note: Also add staining solution to live/dead compensation sample.c.Wash 1x with 150 μL FB and spin down at 550 g for 2 min.Note: Live/dead compensation sample is now ready to use. Live/dead staining.a.Prepare Zombie NIR live/dead staining solution in PBS (see materials and equipment section).b.Add 50 μL of staining solution to cells. Resuspend and incubate for 30 min on ice protected from light.Note: Also add staining solution to live/dead compensation sample.c.Wash 1x with 150 μL FB and spin down at 550 g for 2 min.Note: Live/dead compensation sample is now ready to use. a.Prepare Zombie NIR live/dead staining solution in PBS (see materials and equipment section). Prepare Zombie NIR live/dead staining solution in PBS (see materials and equipment section). b.Add 50 μL of staining solution to cells. Resuspend and incubate for 30 min on ice protected from light.Note: Also add staining solution to live/dead compensation sample. Add 50 μL of staining solution to cells. Resuspend and incubate for 30 min on ice protected from light.Note: Also add staining solution to live/dead compensation sample. Note: Also add staining solution to live/dead compensation sample. c.Wash 1x with 150 μL FB and spin down at 550 g for 2 min.Note: Live/dead compensation sample is now ready to use. Wash 1x with 150 μL FB and spin down at 550 g for 2 min.Note: Live/dead compensation sample is now ready to use. Note: Live/dead compensation sample is now ready to use. 37.Perform BODIPY staining (as described in Step 13). Perform BODIPY staining (as described in Step 13). 38.Prepare single antibody stains for compensation controls (as described in Step 14). Prepare single antibody stains for compensation controls (as described in Step 14). 39.Sample acquisition and analysis.a.Samples can be acquired with flow cytometers that have the following 4 lasers: Violet (405 nm), Blue (488 nm), Yellow/Green (561 nm) and Red (640 nm), such as the BD Fortessa.b.Perform compensation using single stains prepared at Steps 36 to 38.c.Analyze data using the gating strategy proposed in Figure 5 to assess and compare LLM formation between the different conditions tested. Sample acquisition and analysis.a.Samples can be acquired with flow cytometers that have the following 4 lasers: Violet (405 nm), Blue (488 nm), Yellow/Green (561 nm) and Red (640 nm), such as the BD Fortessa.b.Perform compensation using single stains prepared at Steps 36 to 38.c.Analyze data using the gating strategy proposed in Figure 5 to assess and compare LLM formation between the different conditions tested. a.Samples can be acquired with flow cytometers that have the following 4 lasers: Violet (405 nm), Blue (488 nm), Yellow/Green (561 nm) and Red (640 nm), such as the BD Fortessa. Samples can be acquired with flow cytometers that have the following 4 lasers: Violet (405 nm), Blue (488 nm), Yellow/Green (561 nm) and Red (640 nm), such as the BD Fortessa. b.Perform compensation using single stains prepared at Steps 36 to 38. Perform compensation using single stains prepared at Steps 36 to 38. c.Analyze data using the gating strategy proposed in Figure 5 to assess and compare LLM formation between the different conditions tested. Analyze data using the gating strategy proposed in Figure 5 to assess and compare LLM formation between the different conditions tested. Representative flow cytometry gating strategy for assessing in vitro LLM formation Total cells were gated on forward and side scatter (FSC-A and SSC-A) to exclude debris. Single cells were isolated from total cells using FSC-H and FSC-A to exclude doublets. Hereafter, BMDMs were gated from live cells (based on Zombie NIR exclusion) as CD45+CD11b+ cells. LLMs were identified as BODIPYhigh/SSC-Ahigh BMDMs. In vitro assay: Lipid transfer from macrophages to tumor cells Timing: day 1: 1 h; day 2: 6 h This section describes how to assess lipid transfer between macrophages and tumor cells using lipids with a click handle.19 Tracing lipids intercellularly using click chemistry, rather than using lipids tagged with large fluorescent molecules, is crucial to study their physiological function without interfering with their metabolic properties.20 It is important to assess the ability of LLMs to transfer lipids to tumor cells before further probing their functional significance during tumor progression. 40.Load BMDMs with clickable cholesterol.a.Put dTomato+ BMDMs (see Steps 25 to 28 for generating BMDMs) into 2 separate 7 mL Teflon culture bags. Use a concentration of 1.5 × 106 cells per mL; for instance, seed 9 × 106 BMDMs in 6 mL of RPMI lipid transfer media (see materials and equipment section).CRITICAL: To be able to distinguish the two co-cultured cell types (BMDMs and tumor cells) by flow cytometry, at least one of them should be fluorescently labeled, as most extracellular antibody staining for cell type identification are not compatible with this protocol.b.Load one bag of BMDMs with 50 μM alkyne (“clickable”) cholesterol and incubate overnight at 37°C; keep the second bag as negative control.Optional: At this step it is possible to add pharmacological inhibitors for further mechanistic insights, for instance to interfere with lipid efflux or transfer.Alternative: Other lipid species of interest with a click handle can be used instead of cholesterol. Load BMDMs with clickable cholesterol.a.Put dTomato+ BMDMs (see Steps 25 to 28 for generating BMDMs) into 2 separate 7 mL Teflon culture bags. Use a concentration of 1.5 × 106 cells per mL; for instance, seed 9 × 106 BMDMs in 6 mL of RPMI lipid transfer media (see materials and equipment section).CRITICAL: To be able to distinguish the two co-cultured cell types (BMDMs and tumor cells) by flow cytometry, at least one of them should be fluorescently labeled, as most extracellular antibody staining for cell type identification are not compatible with this protocol.b.Load one bag of BMDMs with 50 μM alkyne (“clickable”) cholesterol and incubate overnight at 37°C; keep the second bag as negative control.Optional: At this step it is possible to add pharmacological inhibitors for further mechanistic insights, for instance to interfere with lipid efflux or transfer.Alternative: Other lipid species of interest with a click handle can be used instead of cholesterol. a.Put dTomato+ BMDMs (see Steps 25 to 28 for generating BMDMs) into 2 separate 7 mL Teflon culture bags. Use a concentration of 1.5 × 106 cells per mL; for instance, seed 9 × 106 BMDMs in 6 mL of RPMI lipid transfer media (see materials and equipment section).CRITICAL: To be able to distinguish the two co-cultured cell types (BMDMs and tumor cells) by flow cytometry, at least one of them should be fluorescently labeled, as most extracellular antibody staining for cell type identification are not compatible with this protocol. Put dTomato+ BMDMs (see Steps 25 to 28 for generating BMDMs) into 2 separate 7 mL Teflon culture bags. Use a concentration of 1.5 × 106 cells per mL; for instance, seed 9 × 106 BMDMs in 6 mL of RPMI lipid transfer media (see materials and equipment section).CRITICAL: To be able to distinguish the two co-cultured cell types (BMDMs and tumor cells) by flow cytometry, at least one of them should be fluorescently labeled, as most extracellular antibody staining for cell type identification are not compatible with this protocol. CRITICAL: To be able to distinguish the two co-cultured cell types (BMDMs and tumor cells) by flow cytometry, at least one of them should be fluorescently labeled, as most extracellular antibody staining for cell type identification are not compatible with this protocol. b.Load one bag of BMDMs with 50 μM alkyne (“clickable”) cholesterol and incubate overnight at 37°C; keep the second bag as negative control.Optional: At this step it is possible to add pharmacological inhibitors for further mechanistic insights, for instance to interfere with lipid efflux or transfer.Alternative: Other lipid species of interest with a click handle can be used instead of cholesterol. Load one bag of BMDMs with 50 μM alkyne (“clickable”) cholesterol and incubate overnight at 37°C; keep the second bag as negative control.Optional: At this step it is possible to add pharmacological inhibitors for further mechanistic insights, for instance to interfere with lipid efflux or transfer.Alternative: Other lipid species of interest with a click handle can be used instead of cholesterol. Optional: At this step it is possible to add pharmacological inhibitors for further mechanistic insights, for instance to interfere with lipid efflux or transfer. Alternative: Other lipid species of interest with a click handle can be used instead of cholesterol. 41.Wash BMDMs to remove excess cholesterol.a.Transfer BMDMs from culture bags into 15 mL tubes, spin down at 300 g for 5 min at 4°C and discard supernatant.b.Wash BMDMs with 5 mL washing buffer (see materials and equipment section), spin down at 300 g for 5 min at 4°C and discard supernatant. Repeat this step 5 times.Note: Wash BMDMs at least 5 times with washing buffer as left-over cholesterol leads to high background signal that will interfere with analysis.c.Resuspend BMDMs in RPMI lipid transfer media (see materials and equipment section) at a concentration of 2 × 105 cells per 100 μL. Wash BMDMs to remove excess cholesterol.a.Transfer BMDMs from culture bags into 15 mL tubes, spin down at 300 g for 5 min at 4°C and discard supernatant.b.Wash BMDMs with 5 mL washing buffer (see materials and equipment section), spin down at 300 g for 5 min at 4°C and discard supernatant. Repeat this step 5 times.Note: Wash BMDMs at least 5 times with washing buffer as left-over cholesterol leads to high background signal that will interfere with analysis.c.Resuspend BMDMs in RPMI lipid transfer media (see materials and equipment section) at a concentration of 2 × 105 cells per 100 μL. a.Transfer BMDMs from culture bags into 15 mL tubes, spin down at 300 g for 5 min at 4°C and discard supernatant. Transfer BMDMs from culture bags into 15 mL tubes, spin down at 300 g for 5 min at 4°C and discard supernatant. b.Wash BMDMs with 5 mL washing buffer (see materials and equipment section), spin down at 300 g for 5 min at 4°C and discard supernatant. Repeat this step 5 times.Note: Wash BMDMs at least 5 times with washing buffer as left-over cholesterol leads to high background signal that will interfere with analysis. Wash BMDMs with 5 mL washing buffer (see materials and equipment section), spin down at 300 g for 5 min at 4°C and discard supernatant. Repeat this step 5 times.Note: Wash BMDMs at least 5 times with washing buffer as left-over cholesterol leads to high background signal that will interfere with analysis. Note: Wash BMDMs at least 5 times with washing buffer as left-over cholesterol leads to high background signal that will interfere with analysis. c.Resuspend BMDMs in RPMI lipid transfer media (see materials and equipment section) at a concentration of 2 × 105 cells per 100 μL. Resuspend BMDMs in RPMI lipid transfer media (see materials and equipment section) at a concentration of 2 × 105 cells per 100 μL. 42.Plate tumor cells and BMDMs for co-culture and prepare for flow cytometry staining.a.Collect tumor cells as described in Step 29.b.Count tumor cells and plate 2 × 105 cells per well in a 96-well plate (round bottom) in 100 μL RPMI lipid transfer media.Note: It is possible to use cell types other than tumor cells here to assess cholesterol transfer to different cells of the tumor microenvironment.c.Add 2 × 105 BMDMs to tumor cells for 3 h, 1 h or 0 h. The final volume in each well is 200 μL with 2 × 105 tumor cells and 2 × 105 BMDMs.d.After the incubation time of each time point, spin down cells at 550 g for 2 min and discard supernatant.Note: Time points can be adapted; however, it is important to use the 0-h time point as a control for background signal. For this time point, add BMDMs to tumor cells and spin down immediately to proceed to staining.e.Wash cells 1x with 150 μL PBS, spin down at 550 g for 2 min and discard supernatant.f.Add 50 μL trypsin to wells and incubate for 10 min at 37°C.g.Neutralize trypsin with 50 μL of maintenance media, spin down at 550 g for 2 min and discard supernatant.h.Wash cells 1x with 150 μL PBS, spin down at 550 g for 2 min and discard supernatant. Plate tumor cells and BMDMs for co-culture and prepare for flow cytometry staining.a.Collect tumor cells as described in Step 29.b.Count tumor cells and plate 2 × 105 cells per well in a 96-well plate (round bottom) in 100 μL RPMI lipid transfer media.Note: It is possible to use cell types other than tumor cells here to assess cholesterol transfer to different cells of the tumor microenvironment.c.Add 2 × 105 BMDMs to tumor cells for 3 h, 1 h or 0 h. The final volume in each well is 200 μL with 2 × 105 tumor cells and 2 × 105 BMDMs.d.After the incubation time of each time point, spin down cells at 550 g for 2 min and discard supernatant.Note: Time points can be adapted; however, it is important to use the 0-h time point as a control for background signal. For this time point, add BMDMs to tumor cells and spin down immediately to proceed to staining.e.Wash cells 1x with 150 μL PBS, spin down at 550 g for 2 min and discard supernatant.f.Add 50 μL trypsin to wells and incubate for 10 min at 37°C.g.Neutralize trypsin with 50 μL of maintenance media, spin down at 550 g for 2 min and discard supernatant.h.Wash cells 1x with 150 μL PBS, spin down at 550 g for 2 min and discard supernatant. a.Collect tumor cells as described in Step 29. Collect tumor cells as described in Step 29. b.Count tumor cells and plate 2 × 105 cells per well in a 96-well plate (round bottom) in 100 μL RPMI lipid transfer media.Note: It is possible to use cell types other than tumor cells here to assess cholesterol transfer to different cells of the tumor microenvironment. Count tumor cells and plate 2 × 105 cells per well in a 96-well plate (round bottom) in 100 μL RPMI lipid transfer media.Note: It is possible to use cell types other than tumor cells here to assess cholesterol transfer to different cells of the tumor microenvironment. Note: It is possible to use cell types other than tumor cells here to assess cholesterol transfer to different cells of the tumor microenvironment. c.Add 2 × 105 BMDMs to tumor cells for 3 h, 1 h or 0 h. The final volume in each well is 200 μL with 2 × 105 tumor cells and 2 × 105 BMDMs. Add 2 × 105 BMDMs to tumor cells for 3 h, 1 h or 0 h. The final volume in each well is 200 μL with 2 × 105 tumor cells and 2 × 105 BMDMs. d.After the incubation time of each time point, spin down cells at 550 g for 2 min and discard supernatant.Note: Time points can be adapted; however, it is important to use the 0-h time point as a control for background signal. For this time point, add BMDMs to tumor cells and spin down immediately to proceed to staining. After the incubation time of each time point, spin down cells at 550 g for 2 min and discard supernatant.Note: Time points can be adapted; however, it is important to use the 0-h time point as a control for background signal. For this time point, add BMDMs to tumor cells and spin down immediately to proceed to staining. Note: Time points can be adapted; however, it is important to use the 0-h time point as a control for background signal. For this time point, add BMDMs to tumor cells and spin down immediately to proceed to staining. e.Wash cells 1x with 150 μL PBS, spin down at 550 g for 2 min and discard supernatant. Wash cells 1x with 150 μL PBS, spin down at 550 g for 2 min and discard supernatant. f.Add 50 μL trypsin to wells and incubate for 10 min at 37°C. Add 50 μL trypsin to wells and incubate for 10 min at 37°C. g.Neutralize trypsin with 50 μL of maintenance media, spin down at 550 g for 2 min and discard supernatant. Neutralize trypsin with 50 μL of maintenance media, spin down at 550 g for 2 min and discard supernatant. h.Wash cells 1x with 150 μL PBS, spin down at 550 g for 2 min and discard supernatant. Wash cells 1x with 150 μL PBS, spin down at 550 g for 2 min and discard supernatant. 43.Flow cytometry staining.a.Add 50 μL Zombie Aqua live/dead staining solution (see materials and equipment section) to cells and incubate for 15–30 min on ice protected from light.b.Wash cells 1x with 150 μL FB, spin down at 550 g for 2 min and discard supernatant.CRITICAL: Do not use FB after this step anymore as excess serum can interfere with cholesterol signal.c.Wash cells 1x with 150 μL PBS, spin down at 550 g for 2 min and discard supernatant.d.Fix cells in 50 μL of PFA fixation solution (see materials and equipment section) for 15 min at RT protected from light.e.Wash cells 1x with 150 μL PBS, spin down at 550 g for 2 min and discard supernatant.f.Permeabilize cells by adding 50 μL permeabilization solution (see materials and equipment section) and incubate for 20 min at RT protected from light.g.Wash cells 1x with 150 μL PBS, spin down at 550 g for 2 min and discard supernatant.h.Add 20 μL PBS and prepare the Click-it reaction solution (see materials and equipment section).i.Add 100 μL of Click-it reaction solution to each well and incubate for 30 min at RT protected from light.j.Spin down at 550 g for 2 min and discard supernatant.k.Wash cells 2x with 150 μL washing buffer, spin down at 550 g for 2 min and discard supernatant.l.Resuspend cells in 100 μL washing buffer and proceed to acquisition. Flow cytometry staining.a.Add 50 μL Zombie Aqua live/dead staining solution (see materials and equipment section) to cells and incubate for 15–30 min on ice protected from light.b.Wash cells 1x with 150 μL FB, spin down at 550 g for 2 min and discard supernatant.CRITICAL: Do not use FB after this step anymore as excess serum can interfere with cholesterol signal.c.Wash cells 1x with 150 μL PBS, spin down at 550 g for 2 min and discard supernatant.d.Fix cells in 50 μL of PFA fixation solution (see materials and equipment section) for 15 min at RT protected from light.e.Wash cells 1x with 150 μL PBS, spin down at 550 g for 2 min and discard supernatant.f.Permeabilize cells by adding 50 μL permeabilization solution (see materials and equipment section) and incubate for 20 min at RT protected from light.g.Wash cells 1x with 150 μL PBS, spin down at 550 g for 2 min and discard supernatant.h.Add 20 μL PBS and prepare the Click-it reaction solution (see materials and equipment section).i.Add 100 μL of Click-it reaction solution to each well and incubate for 30 min at RT protected from light.j.Spin down at 550 g for 2 min and discard supernatant.k.Wash cells 2x with 150 μL washing buffer, spin down at 550 g for 2 min and discard supernatant.l.Resuspend cells in 100 μL washing buffer and proceed to acquisition. a.Add 50 μL Zombie Aqua live/dead staining solution (see materials and equipment section) to cells and incubate for 15–30 min on ice protected from light. Add 50 μL Zombie Aqua live/dead staining solution (see materials and equipment section) to cells and incubate for 15–30 min on ice protected from light. b.Wash cells 1x with 150 μL FB, spin down at 550 g for 2 min and discard supernatant.CRITICAL: Do not use FB after this step anymore as excess serum can interfere with cholesterol signal. Wash cells 1x with 150 μL FB, spin down at 550 g for 2 min and discard supernatant.CRITICAL: Do not use FB after this step anymore as excess serum can interfere with cholesterol signal. CRITICAL: Do not use FB after this step anymore as excess serum can interfere with cholesterol signal. c.Wash cells 1x with 150 μL PBS, spin down at 550 g for 2 min and discard supernatant. Wash cells 1x with 150 μL PBS, spin down at 550 g for 2 min and discard supernatant. d.Fix cells in 50 μL of PFA fixation solution (see materials and equipment section) for 15 min at RT protected from light. Fix cells in 50 μL of PFA fixation solution (see materials and equipment section) for 15 min at RT protected from light. e.Wash cells 1x with 150 μL PBS, spin down at 550 g for 2 min and discard supernatant. Wash cells 1x with 150 μL PBS, spin down at 550 g for 2 min and discard supernatant. f.Permeabilize cells by adding 50 μL permeabilization solution (see materials and equipment section) and incubate for 20 min at RT protected from light. Permeabilize cells by adding 50 μL permeabilization solution (see materials and equipment section) and incubate for 20 min at RT protected from light. g.Wash cells 1x with 150 μL PBS, spin down at 550 g for 2 min and discard supernatant. Wash cells 1x with 150 μL PBS, spin down at 550 g for 2 min and discard supernatant. h.Add 20 μL PBS and prepare the Click-it reaction solution (see materials and equipment section). Add 20 μL PBS and prepare the Click-it reaction solution (see materials and equipment section). i.Add 100 μL of Click-it reaction solution to each well and incubate for 30 min at RT protected from light. Add 100 μL of Click-it reaction solution to each well and incubate for 30 min at RT protected from light. j.Spin down at 550 g for 2 min and discard supernatant. Spin down at 550 g for 2 min and discard supernatant. k.Wash cells 2x with 150 μL washing buffer, spin down at 550 g for 2 min and discard supernatant. Wash cells 2x with 150 μL washing buffer, spin down at 550 g for 2 min and discard supernatant. l.Resuspend cells in 100 μL washing buffer and proceed to acquisition. Resuspend cells in 100 μL washing buffer and proceed to acquisition. 44.Sample acquisition and data analysis.a.Samples can be acquired with flow cytometers that have the following 4 lasers: Violet (405 nm), Blue (488 nm), Yellow/Green (561 nm) and Red (640 nm), such as the BD Fortessa.b.Perform compensation using single stains.c.The acquired data can be analyzed using the FlowJo software. Gating strategy can be found in Figure 6. Sample acquisition and data analysis.a.Samples can be acquired with flow cytometers that have the following 4 lasers: Violet (405 nm), Blue (488 nm), Yellow/Green (561 nm) and Red (640 nm), such as the BD Fortessa.b.Perform compensation using single stains.c.The acquired data can be analyzed using the FlowJo software. Gating strategy can be found in Figure 6. a.Samples can be acquired with flow cytometers that have the following 4 lasers: Violet (405 nm), Blue (488 nm), Yellow/Green (561 nm) and Red (640 nm), such as the BD Fortessa. Samples can be acquired with flow cytometers that have the following 4 lasers: Violet (405 nm), Blue (488 nm), Yellow/Green (561 nm) and Red (640 nm), such as the BD Fortessa. b.Perform compensation using single stains. Perform compensation using single stains. c.The acquired data can be analyzed using the FlowJo software. Gating strategy can be found in Figure 6. The acquired data can be analyzed using the FlowJo software. Gating strategy can be found in Figure 6. Representative flow cytometry gating strategy for in vitro cholesterol transfer from BMDMs to tumor cells BMDMs and tumor cells were gated from live cells (Zombie Aqua negative). Tumor cells were identified as dTomato− cells, and mean fluorescent intensity was measured in tumor cells to assess cholesterol uptake following transfer from BMDMs previously loaded with clickable cholesterol at Step 40. In vitro assay to assess pro-proliferative effect of LLMs on tumor cells in co-culture Timing: day 1: 2 h; day 2: 4 h; day 4: 6 h 45.Day 0: Generate TCM as described in Step 29. Day 0: Generate TCM as described in Step 29. 46.Day 1: Plate tumor cells in 6-well plate (the tumor cells used to generate TCM can be re-used for this assay).a.Plate 1 × 105 cells per well of a PDL-coated 6-well plates (prepared as described at Step 30) in maintenance media (see materials and equipment section).CRITICAL: Seeding density must be optimized for each tumor cell type so that tumor cells are sub-confluent by the end of the experiment. This will prevent tumor cells from going into cell cycle arrest by the time of the readout.b.Once tumor cells have fully attached (2–4 h after plating), refresh media with DMEM + P/S without serum to reset cell cycle.c.Incubate at 37°C overnight. Day 1: Plate tumor cells in 6-well plate (the tumor cells used to generate TCM can be re-used for this assay).a.Plate 1 × 105 cells per well of a PDL-coated 6-well plates (prepared as described at Step 30) in maintenance media (see materials and equipment section).CRITICAL: Seeding density must be optimized for each tumor cell type so that tumor cells are sub-confluent by the end of the experiment. This will prevent tumor cells from going into cell cycle arrest by the time of the readout.b.Once tumor cells have fully attached (2–4 h after plating), refresh media with DMEM + P/S without serum to reset cell cycle.c.Incubate at 37°C overnight. a.Plate 1 × 105 cells per well of a PDL-coated 6-well plates (prepared as described at Step 30) in maintenance media (see materials and equipment section).CRITICAL: Seeding density must be optimized for each tumor cell type so that tumor cells are sub-confluent by the end of the experiment. This will prevent tumor cells from going into cell cycle arrest by the time of the readout. Plate 1 × 105 cells per well of a PDL-coated 6-well plates (prepared as described at Step 30) in maintenance media (see materials and equipment section).CRITICAL: Seeding density must be optimized for each tumor cell type so that tumor cells are sub-confluent by the end of the experiment. This will prevent tumor cells from going into cell cycle arrest by the time of the readout. CRITICAL: Seeding density must be optimized for each tumor cell type so that tumor cells are sub-confluent by the end of the experiment. This will prevent tumor cells from going into cell cycle arrest by the time of the readout. b.Once tumor cells have fully attached (2–4 h after plating), refresh media with DMEM + P/S without serum to reset cell cycle. Once tumor cells have fully attached (2–4 h after plating), refresh media with DMEM + P/S without serum to reset cell cycle. c.Incubate at 37°C overnight. Incubate at 37°C overnight. 47.Day 1: Educate BMDMs with TCM.a.Transfer BMDMs from a 30 mL Teflon bag into a 50 mL tube (see Step 28).b.Spin down at 300 g for 5 min.c.Resuspend BMDMs in 10 mL maintenance media and count.d.Transfer 8 × 106 BMDMs to a 15 mL tube, spin down at 300 g for 5 min.Note: The amount of BMDMs needed at this step is dependent on the number of conditions to be tested. Considering two technical replicates, use at least 2 × 105 BMDMs per condition to be tested.e.Remove supernatant and resuspend BMDM pellets in 12 mL TCM.Optional: At this step, it is possible to add pharmacological inhibitors interfering with macrophages’ lipid-laden phenotype (to adjust based on hypothesis). For example, add 200 μM SSO to assess whether blocking the lipid receptor CD36 may affect tumor cell proliferation.f.Divide BMDMs evenly over 2 separate culture bags (max volume of 6 mL per bag) at a concentration of 1 × 106 cells per 1 mL.g.Incubate at 37°C overnight. Day 1: Educate BMDMs with TCM.a.Transfer BMDMs from a 30 mL Teflon bag into a 50 mL tube (see Step 28).b.Spin down at 300 g for 5 min.c.Resuspend BMDMs in 10 mL maintenance media and count.d.Transfer 8 × 106 BMDMs to a 15 mL tube, spin down at 300 g for 5 min.Note: The amount of BMDMs needed at this step is dependent on the number of conditions to be tested. Considering two technical replicates, use at least 2 × 105 BMDMs per condition to be tested.e.Remove supernatant and resuspend BMDM pellets in 12 mL TCM.Optional: At this step, it is possible to add pharmacological inhibitors interfering with macrophages’ lipid-laden phenotype (to adjust based on hypothesis). For example, add 200 μM SSO to assess whether blocking the lipid receptor CD36 may affect tumor cell proliferation.f.Divide BMDMs evenly over 2 separate culture bags (max volume of 6 mL per bag) at a concentration of 1 × 106 cells per 1 mL.g.Incubate at 37°C overnight. a.Transfer BMDMs from a 30 mL Teflon bag into a 50 mL tube (see Step 28). Transfer BMDMs from a 30 mL Teflon bag into a 50 mL tube (see Step 28). b.Spin down at 300 g for 5 min. Spin down at 300 g for 5 min. c.Resuspend BMDMs in 10 mL maintenance media and count. Resuspend BMDMs in 10 mL maintenance media and count. d.Transfer 8 × 106 BMDMs to a 15 mL tube, spin down at 300 g for 5 min.Note: The amount of BMDMs needed at this step is dependent on the number of conditions to be tested. Considering two technical replicates, use at least 2 × 105 BMDMs per condition to be tested. Transfer 8 × 106 BMDMs to a 15 mL tube, spin down at 300 g for 5 min.Note: The amount of BMDMs needed at this step is dependent on the number of conditions to be tested. Considering two technical replicates, use at least 2 × 105 BMDMs per condition to be tested. Note: The amount of BMDMs needed at this step is dependent on the number of conditions to be tested. Considering two technical replicates, use at least 2 × 105 BMDMs per condition to be tested. e.Remove supernatant and resuspend BMDM pellets in 12 mL TCM.Optional: At this step, it is possible to add pharmacological inhibitors interfering with macrophages’ lipid-laden phenotype (to adjust based on hypothesis). For example, add 200 μM SSO to assess whether blocking the lipid receptor CD36 may affect tumor cell proliferation. Remove supernatant and resuspend BMDM pellets in 12 mL TCM.Optional: At this step, it is possible to add pharmacological inhibitors interfering with macrophages’ lipid-laden phenotype (to adjust based on hypothesis). For example, add 200 μM SSO to assess whether blocking the lipid receptor CD36 may affect tumor cell proliferation. Optional: At this step, it is possible to add pharmacological inhibitors interfering with macrophages’ lipid-laden phenotype (to adjust based on hypothesis). For example, add 200 μM SSO to assess whether blocking the lipid receptor CD36 may affect tumor cell proliferation. f.Divide BMDMs evenly over 2 separate culture bags (max volume of 6 mL per bag) at a concentration of 1 × 106 cells per 1 mL. Divide BMDMs evenly over 2 separate culture bags (max volume of 6 mL per bag) at a concentration of 1 × 106 cells per 1 mL. g.Incubate at 37°C overnight. Incubate at 37°C overnight. 48.Day 2: Load BMDMs with lipid source (for e.g., myelin debris as described at Step 32).a.Add 1 mg/mL myelin debris to one of the two bags, or same volume of PBS to the other bag (vehicle control).b.Incubate at 37°C for 3 h. Day 2: Load BMDMs with lipid source (for e.g., myelin debris as described at Step 32).a.Add 1 mg/mL myelin debris to one of the two bags, or same volume of PBS to the other bag (vehicle control).b.Incubate at 37°C for 3 h. a.Add 1 mg/mL myelin debris to one of the two bags, or same volume of PBS to the other bag (vehicle control). Add 1 mg/mL myelin debris to one of the two bags, or same volume of PBS to the other bag (vehicle control). b.Incubate at 37°C for 3 h. Incubate at 37°C for 3 h. 49.Day 2: Co-culture BMDMs with tumor cells.a.Transfer BMDMs from bag into a 15 mL tube.b.Spin down at 300 g for 5 min.c.Resuspend BMDMs in 10 mL low-serum media and count.d.Aspirate media from 6-well plates containing the tumor cells.e.Add 1 × 105 BMDMs per well in 2 mL of low-serum media.Note: Also include tumor cell mono-culture conditions. Add 2 mL low-serum media with no BMDMs.f.Incubate at 37°C for 48 h. Day 2: Co-culture BMDMs with tumor cells.a.Transfer BMDMs from bag into a 15 mL tube.b.Spin down at 300 g for 5 min.c.Resuspend BMDMs in 10 mL low-serum media and count.d.Aspirate media from 6-well plates containing the tumor cells.e.Add 1 × 105 BMDMs per well in 2 mL of low-serum media.Note: Also include tumor cell mono-culture conditions. Add 2 mL low-serum media with no BMDMs.f.Incubate at 37°C for 48 h. a.Transfer BMDMs from bag into a 15 mL tube. Transfer BMDMs from bag into a 15 mL tube. b.Spin down at 300 g for 5 min. Spin down at 300 g for 5 min. c.Resuspend BMDMs in 10 mL low-serum media and count. Resuspend BMDMs in 10 mL low-serum media and count. d.Aspirate media from 6-well plates containing the tumor cells. Aspirate media from 6-well plates containing the tumor cells. e.Add 1 × 105 BMDMs per well in 2 mL of low-serum media.Note: Also include tumor cell mono-culture conditions. Add 2 mL low-serum media with no BMDMs. Add 1 × 105 BMDMs per well in 2 mL of low-serum media.Note: Also include tumor cell mono-culture conditions. Add 2 mL low-serum media with no BMDMs. Note: Also include tumor cell mono-culture conditions. Add 2 mL low-serum media with no BMDMs. f.Incubate at 37°C for 48 h. Incubate at 37°C for 48 h. 50.Day 4: Incubate cells with EdU.a.Prepare 10 μM EdU solution by diluting the frozen EdU stock solution in low-serum media.CRITICAL: To ensure complete solubilization of EdU, the stock solution needs to be thawed in a water bath and rigorously resuspended in pre-warmed media, until the solution is clear and free from precipitates.b.Aspirate medium from wells and replace with 2 mL 10 μM EdU solution. Incubate for 30 min at 37°C. Day 4: Incubate cells with EdU.a.Prepare 10 μM EdU solution by diluting the frozen EdU stock solution in low-serum media.CRITICAL: To ensure complete solubilization of EdU, the stock solution needs to be thawed in a water bath and rigorously resuspended in pre-warmed media, until the solution is clear and free from precipitates.b.Aspirate medium from wells and replace with 2 mL 10 μM EdU solution. Incubate for 30 min at 37°C. a.Prepare 10 μM EdU solution by diluting the frozen EdU stock solution in low-serum media.CRITICAL: To ensure complete solubilization of EdU, the stock solution needs to be thawed in a water bath and rigorously resuspended in pre-warmed media, until the solution is clear and free from precipitates. Prepare 10 μM EdU solution by diluting the frozen EdU stock solution in low-serum media.CRITICAL: To ensure complete solubilization of EdU, the stock solution needs to be thawed in a water bath and rigorously resuspended in pre-warmed media, until the solution is clear and free from precipitates. CRITICAL: To ensure complete solubilization of EdU, the stock solution needs to be thawed in a water bath and rigorously resuspended in pre-warmed media, until the solution is clear and free from precipitates. b.Aspirate medium from wells and replace with 2 mL 10 μM EdU solution. Incubate for 30 min at 37°C. Aspirate medium from wells and replace with 2 mL 10 μM EdU solution. Incubate for 30 min at 37°C. 51.Harvest cells for flow cytometry staining.a.Remove medium from wells and wash 1x with 1 mL of PBS.b.Add 500 μL trypsin per well, incubate cells for 10 min at 37°C.c.Check under the microscope to ensure that most cells are detached.d.Inhibit trypsin with 500 μL of maintenance medium in each well.e.Use a p1000 tip to scrape off BMDMs that remain attached.f.Flush the wells with a p1000 to detach any remaining BMDMs and tumor cells and transfer to 1.5 mL Eppendorf tube.g.Spin 5 min at 300 g.h.Remove supernatant, leave around 100 μL and resuspend pellet. Harvest cells for flow cytometry staining.a.Remove medium from wells and wash 1x with 1 mL of PBS.b.Add 500 μL trypsin per well, incubate cells for 10 min at 37°C.c.Check under the microscope to ensure that most cells are detached.d.Inhibit trypsin with 500 μL of maintenance medium in each well.e.Use a p1000 tip to scrape off BMDMs that remain attached.f.Flush the wells with a p1000 to detach any remaining BMDMs and tumor cells and transfer to 1.5 mL Eppendorf tube.g.Spin 5 min at 300 g.h.Remove supernatant, leave around 100 μL and resuspend pellet. a.Remove medium from wells and wash 1x with 1 mL of PBS. Remove medium from wells and wash 1x with 1 mL of PBS. b.Add 500 μL trypsin per well, incubate cells for 10 min at 37°C. Add 500 μL trypsin per well, incubate cells for 10 min at 37°C. c.Check under the microscope to ensure that most cells are detached. Check under the microscope to ensure that most cells are detached. d.Inhibit trypsin with 500 μL of maintenance medium in each well. Inhibit trypsin with 500 μL of maintenance medium in each well. e.Use a p1000 tip to scrape off BMDMs that remain attached. Use a p1000 tip to scrape off BMDMs that remain attached. f.Flush the wells with a p1000 to detach any remaining BMDMs and tumor cells and transfer to 1.5 mL Eppendorf tube. Flush the wells with a p1000 to detach any remaining BMDMs and tumor cells and transfer to 1.5 mL Eppendorf tube. g.Spin 5 min at 300 g. Spin 5 min at 300 g. h.Remove supernatant, leave around 100 μL and resuspend pellet. Remove supernatant, leave around 100 μL and resuspend pellet. 52.Proceed with FACS staining.a.Transfer single-cell suspension to 96-well plate (round bottom).CRITICAL: Split single cell suspension into multiple wells for compensation samples that require cells (i.e. unstained sample, live/dead compensation samples).b.Spin down plate at 550 g for 2 min and remove supernatant by inverting plate and tapping it dry on a paper towel.c.Wash cells with 150 μL FB, spin down at 550 g for 2 min and discard supernatant. Proceed with FACS staining.a.Transfer single-cell suspension to 96-well plate (round bottom).CRITICAL: Split single cell suspension into multiple wells for compensation samples that require cells (i.e. unstained sample, live/dead compensation samples).b.Spin down plate at 550 g for 2 min and remove supernatant by inverting plate and tapping it dry on a paper towel.c.Wash cells with 150 μL FB, spin down at 550 g for 2 min and discard supernatant. a.Transfer single-cell suspension to 96-well plate (round bottom).CRITICAL: Split single cell suspension into multiple wells for compensation samples that require cells (i.e. unstained sample, live/dead compensation samples). Transfer single-cell suspension to 96-well plate (round bottom).CRITICAL: Split single cell suspension into multiple wells for compensation samples that require cells (i.e. unstained sample, live/dead compensation samples). CRITICAL: Split single cell suspension into multiple wells for compensation samples that require cells (i.e. unstained sample, live/dead compensation samples). b.Spin down plate at 550 g for 2 min and remove supernatant by inverting plate and tapping it dry on a paper towel. Spin down plate at 550 g for 2 min and remove supernatant by inverting plate and tapping it dry on a paper towel. c.Wash cells with 150 μL FB, spin down at 550 g for 2 min and discard supernatant. Wash cells with 150 μL FB, spin down at 550 g for 2 min and discard supernatant. 53.Sample blocking and antibody staining.a.Block sample by resuspending cells in 50 μL blocking buffer (see materials and equipment section) and incubate for 15–30 min on ice.b.Spin down plate at 550 g for 2 min and remove supernatant.c.Add 50 μL of antibody mix 5 per well and incubate for 15–30 min on ice protected from light.CRITICAL: For live/dead compensation sample, add 100 μL fixation solution (see materials and equipment section) instead of antibody mix 5 during staining process.d.Spin down at 550 g for 2 min and remove supernatant, wash 1x in FB and 1x in PBS.Note: It is important to wash cells in PBS prior to live/dead staining to remove any traces of serum. Sample blocking and antibody staining.a.Block sample by resuspending cells in 50 μL blocking buffer (see materials and equipment section) and incubate for 15–30 min on ice.b.Spin down plate at 550 g for 2 min and remove supernatant.c.Add 50 μL of antibody mix 5 per well and incubate for 15–30 min on ice protected from light.CRITICAL: For live/dead compensation sample, add 100 μL fixation solution (see materials and equipment section) instead of antibody mix 5 during staining process.d.Spin down at 550 g for 2 min and remove supernatant, wash 1x in FB and 1x in PBS.Note: It is important to wash cells in PBS prior to live/dead staining to remove any traces of serum. a.Block sample by resuspending cells in 50 μL blocking buffer (see materials and equipment section) and incubate for 15–30 min on ice. Block sample by resuspending cells in 50 μL blocking buffer (see materials and equipment section) and incubate for 15–30 min on ice. b.Spin down plate at 550 g for 2 min and remove supernatant. Spin down plate at 550 g for 2 min and remove supernatant. c.Add 50 μL of antibody mix 5 per well and incubate for 15–30 min on ice protected from light.CRITICAL: For live/dead compensation sample, add 100 μL fixation solution (see materials and equipment section) instead of antibody mix 5 during staining process. Add 50 μL of antibody mix 5 per well and incubate for 15–30 min on ice protected from light.CRITICAL: For live/dead compensation sample, add 100 μL fixation solution (see materials and equipment section) instead of antibody mix 5 during staining process. CRITICAL: For live/dead compensation sample, add 100 μL fixation solution (see materials and equipment section) instead of antibody mix 5 during staining process. d.Spin down at 550 g for 2 min and remove supernatant, wash 1x in FB and 1x in PBS.Note: It is important to wash cells in PBS prior to live/dead staining to remove any traces of serum. Spin down at 550 g for 2 min and remove supernatant, wash 1x in FB and 1x in PBS.Note: It is important to wash cells in PBS prior to live/dead staining to remove any traces of serum. Note: It is important to wash cells in PBS prior to live/dead staining to remove any traces of serum. 54.Live/dead staining.a.Prepare Zombie NIR live/dead staining solution in PBS (see materials and equipment section).b.Add 50 μL of staining solution to cells. Resuspend and incubate for 30 min on ice protected from light.Note: Also add staining solution to live/dead compensation sample.c.Wash 1x with 150 μL FB and spin down at 550 g for 2 min.Note: Live/dead compensation sample is now ready to use. Live/dead staining.a.Prepare Zombie NIR live/dead staining solution in PBS (see materials and equipment section).b.Add 50 μL of staining solution to cells. Resuspend and incubate for 30 min on ice protected from light.Note: Also add staining solution to live/dead compensation sample.c.Wash 1x with 150 μL FB and spin down at 550 g for 2 min.Note: Live/dead compensation sample is now ready to use. a.Prepare Zombie NIR live/dead staining solution in PBS (see materials and equipment section). Prepare Zombie NIR live/dead staining solution in PBS (see materials and equipment section). b.Add 50 μL of staining solution to cells. Resuspend and incubate for 30 min on ice protected from light.Note: Also add staining solution to live/dead compensation sample. Add 50 μL of staining solution to cells. Resuspend and incubate for 30 min on ice protected from light.Note: Also add staining solution to live/dead compensation sample. Note: Also add staining solution to live/dead compensation sample. c.Wash 1x with 150 μL FB and spin down at 550 g for 2 min.Note: Live/dead compensation sample is now ready to use. Wash 1x with 150 μL FB and spin down at 550 g for 2 min.Note: Live/dead compensation sample is now ready to use. Note: Live/dead compensation sample is now ready to use. 55.Fix cells.a.Wash 1x with PBS, spin at 550 g for 2 min and discard supernatant.b.Add 20 μL of PBS to well.c.Very slowly pipette 150 μL of ice-cold 70% ethanol on the samples while constantly mixing with a second p200 pipette.CRITICAL: It is crucial to mix the cell suspension while adding ethanol, to prevent cells from sticking during fixation. Increasing the ethanol gradient too fast can lead to cell damage; therefore, it is important to perform this step at a slow pace.d.Incubate for 1 h at 4°C protected from light. Fix cells.a.Wash 1x with PBS, spin at 550 g for 2 min and discard supernatant.b.Add 20 μL of PBS to well.c.Very slowly pipette 150 μL of ice-cold 70% ethanol on the samples while constantly mixing with a second p200 pipette.CRITICAL: It is crucial to mix the cell suspension while adding ethanol, to prevent cells from sticking during fixation. Increasing the ethanol gradient too fast can lead to cell damage; therefore, it is important to perform this step at a slow pace.d.Incubate for 1 h at 4°C protected from light. a.Wash 1x with PBS, spin at 550 g for 2 min and discard supernatant. Wash 1x with PBS, spin at 550 g for 2 min and discard supernatant. b.Add 20 μL of PBS to well. Add 20 μL of PBS to well. c.Very slowly pipette 150 μL of ice-cold 70% ethanol on the samples while constantly mixing with a second p200 pipette.CRITICAL: It is crucial to mix the cell suspension while adding ethanol, to prevent cells from sticking during fixation. Increasing the ethanol gradient too fast can lead to cell damage; therefore, it is important to perform this step at a slow pace. Very slowly pipette 150 μL of ice-cold 70% ethanol on the samples while constantly mixing with a second p200 pipette.CRITICAL: It is crucial to mix the cell suspension while adding ethanol, to prevent cells from sticking during fixation. Increasing the ethanol gradient too fast can lead to cell damage; therefore, it is important to perform this step at a slow pace. CRITICAL: It is crucial to mix the cell suspension while adding ethanol, to prevent cells from sticking during fixation. Increasing the ethanol gradient too fast can lead to cell damage; therefore, it is important to perform this step at a slow pace. d.Incubate for 1 h at 4°C protected from light. Incubate for 1 h at 4°C protected from light. 56.Perform click reaction to stain EdU in proliferating cells.a.Wash 2x with PBST (PBS + 0.1% Tween) and 1x with PBS.b.Resuspend in 20 μL SAB (see materials and equipment section).c.Add 100 μL of click-it cocktail per well (see materials and equipment section) and incubate 30 min at RT protected from light.d.Wash 2x with FB. Perform click reaction to stain EdU in proliferating cells.a.Wash 2x with PBST (PBS + 0.1% Tween) and 1x with PBS.b.Resuspend in 20 μL SAB (see materials and equipment section).c.Add 100 μL of click-it cocktail per well (see materials and equipment section) and incubate 30 min at RT protected from light.d.Wash 2x with FB. a.Wash 2x with PBST (PBS + 0.1% Tween) and 1x with PBS. Wash 2x with PBST (PBS + 0.1% Tween) and 1x with PBS. b.Resuspend in 20 μL SAB (see materials and equipment section). Resuspend in 20 μL SAB (see materials and equipment section). c.Add 100 μL of click-it cocktail per well (see materials and equipment section) and incubate 30 min at RT protected from light. Add 100 μL of click-it cocktail per well (see materials and equipment section) and incubate 30 min at RT protected from light. d.Wash 2x with FB. Wash 2x with FB. 57.Resuspend samples in 100 μL SAB + 0.1 μL RNase A + 0.1 μL propidium iodine (PI). Resuspend samples in 100 μL SAB + 0.1 μL RNase A + 0.1 μL propidium iodine (PI). 58.Data acquisition and analysis.a.Samples can be acquired with flow cytometers that have the following 4 lasers: Violet (405 nm), Blue (488 nm), Yellow/Green (561 nm) and Red (640 nm), such as the BD Fortessa.b.Perform compensation using single stains.c.Analyze data using the gating strategy proposed in Figure 7 to assess and compare LLM effect on tumor cell proliferation. Data acquisition and analysis.a.Samples can be acquired with flow cytometers that have the following 4 lasers: Violet (405 nm), Blue (488 nm), Yellow/Green (561 nm) and Red (640 nm), such as the BD Fortessa.b.Perform compensation using single stains.c.Analyze data using the gating strategy proposed in Figure 7 to assess and compare LLM effect on tumor cell proliferation. a.Samples can be acquired with flow cytometers that have the following 4 lasers: Violet (405 nm), Blue (488 nm), Yellow/Green (561 nm) and Red (640 nm), such as the BD Fortessa. Samples can be acquired with flow cytometers that have the following 4 lasers: Violet (405 nm), Blue (488 nm), Yellow/Green (561 nm) and Red (640 nm), such as the BD Fortessa. b.Perform compensation using single stains. Perform compensation using single stains. c.Analyze data using the gating strategy proposed in Figure 7 to assess and compare LLM effect on tumor cell proliferation. Analyze data using the gating strategy proposed in Figure 7 to assess and compare LLM effect on tumor cell proliferation. Representative flow cytometry gating strategy for identifying EdU positive tumor cells BMDMs and tumor cells were gated from live cells (Zombie NIR-). Tumor cells were identified based on CD45−/CD11b− signal. Polyploid and hypoploid cells were gated out based on PI signal (reflecting DNA content), and EdU+ cells were gated from diploid (2n) cells. Ex vivo assays to assess LLM formation and functional significance Timing: day 1: 5 h; day 2: 2 h; day 3/4: 6 h This section describes the steps to functionally validate the role of lipid uptake and transfer between macrophages and tumor cells in an ex vivo setting, in which in vivo tumors are used as single cell preparations in culture. After dissociation of the tumor, various parameters are changed through positive selection steps, including for instance removing/re-adding myelin debris or macrophages from the whole dissociated tumor, to assess their impact on the phenotypes observed. Alternative options have been included depending on the hypotheses generated in previous steps. 59.Tumor dissociation and isolation of myelin.a.See Steps 1 to 8 for tumor dissociation. Using tumors from mice that are at endpoint (maximum tumor size) ensures that enough material is available for all conditions mentioned hereafter.b.After tumor dissociation, which includes a myelin removal step (see in vivo flow cytometry protocol Step 9), collect the isolated myelin by removing LS column from the magnet and flushing it with 2 mL FB into a 2 mL Eppendorf tube.i.Spin down at 14000 g for 15 min.ii.Discard supernatant.iii.Resuspend in 20 μL PBS.c.Snap freeze myelin on dry ice and store at −80°C. Tumor dissociation and isolation of myelin.a.See Steps 1 to 8 for tumor dissociation. Using tumors from mice that are at endpoint (maximum tumor size) ensures that enough material is available for all conditions mentioned hereafter.b.After tumor dissociation, which includes a myelin removal step (see in vivo flow cytometry protocol Step 9), collect the isolated myelin by removing LS column from the magnet and flushing it with 2 mL FB into a 2 mL Eppendorf tube.i.Spin down at 14000 g for 15 min.ii.Discard supernatant.iii.Resuspend in 20 μL PBS.c.Snap freeze myelin on dry ice and store at −80°C. a.See Steps 1 to 8 for tumor dissociation. Using tumors from mice that are at endpoint (maximum tumor size) ensures that enough material is available for all conditions mentioned hereafter. See Steps 1 to 8 for tumor dissociation. Using tumors from mice that are at endpoint (maximum tumor size) ensures that enough material is available for all conditions mentioned hereafter. b.After tumor dissociation, which includes a myelin removal step (see in vivo flow cytometry protocol Step 9), collect the isolated myelin by removing LS column from the magnet and flushing it with 2 mL FB into a 2 mL Eppendorf tube.i.Spin down at 14000 g for 15 min.ii.Discard supernatant.iii.Resuspend in 20 μL PBS. After tumor dissociation, which includes a myelin removal step (see in vivo flow cytometry protocol Step 9), collect the isolated myelin by removing LS column from the magnet and flushing it with 2 mL FB into a 2 mL Eppendorf tube.i.Spin down at 14000 g for 15 min.ii.Discard supernatant.iii.Resuspend in 20 μL PBS. i.Spin down at 14000 g for 15 min. Spin down at 14000 g for 15 min. ii.Discard supernatant. Discard supernatant. iii.Resuspend in 20 μL PBS. Resuspend in 20 μL PBS. c.Snap freeze myelin on dry ice and store at −80°C. Snap freeze myelin on dry ice and store at −80°C. 60.CD11b+ cell removal by positive selection.a.Split the tumor cell suspension (obtained in Step 59a) in two samples.b.Spin down at 300 g for 5 min and discard supernatant.c.Incubate one of the samples with CD11b removal beads mixture (see materials and equipment section) for 15 min on ice.CRITICAL: Perform this step only for one of the two samples, to allow comparison between full tumor and tumor lacking CD11b+ myeloid cells. Keep the other tumor sample in 2 mL FB on ice during this procedure.d.Add 18 mL FB to samples, spin down at 300 g for 5 min at 4°C and discard supernatant.e.Resuspend cells in 1 mL FB, run through magnetic LS column and collect flowthrough.f.Wash column 3x with 2 mL FB and collect flowthrough in the same tube.Note: The flowthrough contains all CD11b negative cells.g.Remove column from magnet and flush with 4 mL FB in new tube to collect purified CD11b+ cells.h.This procedure will result in 3 different conditions:i.Tumor with CD11b+ cells (no myelin).ii.Tumor without CD11b+ cells (no myelin).iii.CD11b+ cells alone (no myelin). CD11b+ cell removal by positive selection.a.Split the tumor cell suspension (obtained in Step 59a) in two samples.b.Spin down at 300 g for 5 min and discard supernatant.c.Incubate one of the samples with CD11b removal beads mixture (see materials and equipment section) for 15 min on ice.CRITICAL: Perform this step only for one of the two samples, to allow comparison between full tumor and tumor lacking CD11b+ myeloid cells. Keep the other tumor sample in 2 mL FB on ice during this procedure.d.Add 18 mL FB to samples, spin down at 300 g for 5 min at 4°C and discard supernatant.e.Resuspend cells in 1 mL FB, run through magnetic LS column and collect flowthrough.f.Wash column 3x with 2 mL FB and collect flowthrough in the same tube.Note: The flowthrough contains all CD11b negative cells.g.Remove column from magnet and flush with 4 mL FB in new tube to collect purified CD11b+ cells.h.This procedure will result in 3 different conditions:i.Tumor with CD11b+ cells (no myelin).ii.Tumor without CD11b+ cells (no myelin).iii.CD11b+ cells alone (no myelin). a.Split the tumor cell suspension (obtained in Step 59a) in two samples. Split the tumor cell suspension (obtained in Step 59a) in two samples. b.Spin down at 300 g for 5 min and discard supernatant. Spin down at 300 g for 5 min and discard supernatant. c.Incubate one of the samples with CD11b removal beads mixture (see materials and equipment section) for 15 min on ice.CRITICAL: Perform this step only for one of the two samples, to allow comparison between full tumor and tumor lacking CD11b+ myeloid cells. Keep the other tumor sample in 2 mL FB on ice during this procedure. Incubate one of the samples with CD11b removal beads mixture (see materials and equipment section) for 15 min on ice.CRITICAL: Perform this step only for one of the two samples, to allow comparison between full tumor and tumor lacking CD11b+ myeloid cells. Keep the other tumor sample in 2 mL FB on ice during this procedure. CRITICAL: Perform this step only for one of the two samples, to allow comparison between full tumor and tumor lacking CD11b+ myeloid cells. Keep the other tumor sample in 2 mL FB on ice during this procedure. d.Add 18 mL FB to samples, spin down at 300 g for 5 min at 4°C and discard supernatant. Add 18 mL FB to samples, spin down at 300 g for 5 min at 4°C and discard supernatant. e.Resuspend cells in 1 mL FB, run through magnetic LS column and collect flowthrough. Resuspend cells in 1 mL FB, run through magnetic LS column and collect flowthrough. f.Wash column 3x with 2 mL FB and collect flowthrough in the same tube.Note: The flowthrough contains all CD11b negative cells. Wash column 3x with 2 mL FB and collect flowthrough in the same tube.Note: The flowthrough contains all CD11b negative cells. Note: The flowthrough contains all CD11b negative cells. g.Remove column from magnet and flush with 4 mL FB in new tube to collect purified CD11b+ cells. Remove column from magnet and flush with 4 mL FB in new tube to collect purified CD11b+ cells. h.This procedure will result in 3 different conditions:i.Tumor with CD11b+ cells (no myelin).ii.Tumor without CD11b+ cells (no myelin).iii.CD11b+ cells alone (no myelin). This procedure will result in 3 different conditions:i.Tumor with CD11b+ cells (no myelin).ii.Tumor without CD11b+ cells (no myelin).iii.CD11b+ cells alone (no myelin). i.Tumor with CD11b+ cells (no myelin). Tumor with CD11b+ cells (no myelin). ii.Tumor without CD11b+ cells (no myelin). Tumor without CD11b+ cells (no myelin). iii.CD11b+ cells alone (no myelin). CD11b+ cells alone (no myelin). 61.Plate cells for ex vivo experiment.a.Divide each of the 3 conditions listed above over 2 wells (in which myelin will be re-introduced or not).b.Spin down the tubes containing the flowthrough (Steps 60e and 60f) at 300 g for 5 min at 4°C.c.Resuspend each pellet in 2 mL of maintenance media.d.Plate 1 mL (containing roughly 5 × 105 cells) per well of a 12-well plate. Plate cells for ex vivo experiment.a.Divide each of the 3 conditions listed above over 2 wells (in which myelin will be re-introduced or not).b.Spin down the tubes containing the flowthrough (Steps 60e and 60f) at 300 g for 5 min at 4°C.c.Resuspend each pellet in 2 mL of maintenance media.d.Plate 1 mL (containing roughly 5 × 105 cells) per well of a 12-well plate. a.Divide each of the 3 conditions listed above over 2 wells (in which myelin will be re-introduced or not). Divide each of the 3 conditions listed above over 2 wells (in which myelin will be re-introduced or not). b.Spin down the tubes containing the flowthrough (Steps 60e and 60f) at 300 g for 5 min at 4°C. Spin down the tubes containing the flowthrough (Steps 60e and 60f) at 300 g for 5 min at 4°C. c.Resuspend each pellet in 2 mL of maintenance media. Resuspend each pellet in 2 mL of maintenance media. d.Plate 1 mL (containing roughly 5 × 105 cells) per well of a 12-well plate. Plate 1 mL (containing roughly 5 × 105 cells) per well of a 12-well plate. Note: The well size can be adapted depending on the size of the tumor, to ensure optimal (sub-confluent) cell density. 62.Selection of downstream assays.Note: The selection of downstream assays depends on whether the readout is focused on BMDMs or tumor cells. In this protocol, two examples of downstream assays are proposed: 1) ex vivo LLM formation, which is focused on BMDMs for the readout, and 2) ex vivo EdU staining which is focused on tumor cells for the readout. However, all assays described in the in vitro section can be adapted to the ex vivo setting using this procedure.a.To assess LLM formation of dTomato+ BMDMs, proceed as follow:Optional: It is possible to add more conditions and perform the co-culture with genetically-edited macrophages or pharmacological inhibitors to assess their effects on LLM formation.i.Prepare differentiated dTomato+ BMDMs (as described in Steps 25 to 28).ii.24 h after plating the dissociated tumor (as described in Step 61d), remove the media from each well.iii.Add 1.5 × 105 BMDMs per well in 1 mL of fresh maintenance media supplemented with 10 ng/mL CSF-1.Note: It is important to use fluorescently labeled BMDMs to be able to distinguish them from the macrophages already present within the dissociated tumor.Alternative: Media from tumor plates can be collected and BMDMs can be exposed to this collected tumor-conditioned media instead of performing a co-culture assay.iv.Add myelin debris (isolated during Step 59b) to one well of each condition, distributing it equally among the conditions (i.e., if tumor was split into 6 conditions, add 1/6 of collected myelin debris per condition).v.Incubate for 48 h at 37°C.vi.Proceed to LLM staining as described in Steps 33 to 39.b.To assess proliferation of tumor cells after BMDM co-culture, proceed as follow:i.24 h after plating the dissociated tumor (Step 61d), replace media with low-serum media and add myelin debris to one well of each condition, distributing it equally among the conditions as described above.Optional: Instead of using low-serum media, this assay can be performed with lipid-free medium (see materials and equipment section). Alternatively, both media can be tested if each tumor condition was split into 4 instead of into 2 parts.ii.Incubate for 48 h at 37°C.iii.Perform EdU staining as described in Steps 50 to 58 to assess tumor cell and/or BMDM proliferation. Selection of downstream assays.Note: The selection of downstream assays depends on whether the readout is focused on BMDMs or tumor cells. In this protocol, two examples of downstream assays are proposed: 1) ex vivo LLM formation, which is focused on BMDMs for the readout, and 2) ex vivo EdU staining which is focused on tumor cells for the readout. However, all assays described in the in vitro section can be adapted to the ex vivo setting using this procedure.a.To assess LLM formation of dTomato+ BMDMs, proceed as follow:Optional: It is possible to add more conditions and perform the co-culture with genetically-edited macrophages or pharmacological inhibitors to assess their effects on LLM formation.i.Prepare differentiated dTomato+ BMDMs (as described in Steps 25 to 28).ii.24 h after plating the dissociated tumor (as described in Step 61d), remove the media from each well.iii.Add 1.5 × 105 BMDMs per well in 1 mL of fresh maintenance media supplemented with 10 ng/mL CSF-1.Note: It is important to use fluorescently labeled BMDMs to be able to distinguish them from the macrophages already present within the dissociated tumor.Alternative: Media from tumor plates can be collected and BMDMs can be exposed to this collected tumor-conditioned media instead of performing a co-culture assay.iv.Add myelin debris (isolated during Step 59b) to one well of each condition, distributing it equally among the conditions (i.e., if tumor was split into 6 conditions, add 1/6 of collected myelin debris per condition).v.Incubate for 48 h at 37°C.vi.Proceed to LLM staining as described in Steps 33 to 39.b.To assess proliferation of tumor cells after BMDM co-culture, proceed as follow:i.24 h after plating the dissociated tumor (Step 61d), replace media with low-serum media and add myelin debris to one well of each condition, distributing it equally among the conditions as described above.Optional: Instead of using low-serum media, this assay can be performed with lipid-free medium (see materials and equipment section). Alternatively, both media can be tested if each tumor condition was split into 4 instead of into 2 parts.ii.Incubate for 48 h at 37°C.iii.Perform EdU staining as described in Steps 50 to 58 to assess tumor cell and/or BMDM proliferation. Note: The selection of downstream assays depends on whether the readout is focused on BMDMs or tumor cells. In this protocol, two examples of downstream assays are proposed: 1) ex vivo LLM formation, which is focused on BMDMs for the readout, and 2) ex vivo EdU staining which is focused on tumor cells for the readout. However, all assays described in the in vitro section can be adapted to the ex vivo setting using this procedure. a.To assess LLM formation of dTomato+ BMDMs, proceed as follow:Optional: It is possible to add more conditions and perform the co-culture with genetically-edited macrophages or pharmacological inhibitors to assess their effects on LLM formation.i.Prepare differentiated dTomato+ BMDMs (as described in Steps 25 to 28).ii.24 h after plating the dissociated tumor (as described in Step 61d), remove the media from each well.iii.Add 1.5 × 105 BMDMs per well in 1 mL of fresh maintenance media supplemented with 10 ng/mL CSF-1.Note: It is important to use fluorescently labeled BMDMs to be able to distinguish them from the macrophages already present within the dissociated tumor.Alternative: Media from tumor plates can be collected and BMDMs can be exposed to this collected tumor-conditioned media instead of performing a co-culture assay.iv.Add myelin debris (isolated during Step 59b) to one well of each condition, distributing it equally among the conditions (i.e., if tumor was split into 6 conditions, add 1/6 of collected myelin debris per condition).v.Incubate for 48 h at 37°C.vi.Proceed to LLM staining as described in Steps 33 to 39. To assess LLM formation of dTomato+ BMDMs, proceed as follow:Optional: It is possible to add more conditions and perform the co-culture with genetically-edited macrophages or pharmacological inhibitors to assess their effects on LLM formation.i.Prepare differentiated dTomato+ BMDMs (as described in Steps 25 to 28).ii.24 h after plating the dissociated tumor (as described in Step 61d), remove the media from each well.iii.Add 1.5 × 105 BMDMs per well in 1 mL of fresh maintenance media supplemented with 10 ng/mL CSF-1.Note: It is important to use fluorescently labeled BMDMs to be able to distinguish them from the macrophages already present within the dissociated tumor.Alternative: Media from tumor plates can be collected and BMDMs can be exposed to this collected tumor-conditioned media instead of performing a co-culture assay.iv.Add myelin debris (isolated during Step 59b) to one well of each condition, distributing it equally among the conditions (i.e., if tumor was split into 6 conditions, add 1/6 of collected myelin debris per condition).v.Incubate for 48 h at 37°C.vi.Proceed to LLM staining as described in Steps 33 to 39. Optional: It is possible to add more conditions and perform the co-culture with genetically-edited macrophages or pharmacological inhibitors to assess their effects on LLM formation. i.Prepare differentiated dTomato+ BMDMs (as described in Steps 25 to 28). Prepare differentiated dTomato+ BMDMs (as described in Steps 25 to 28). ii.24 h after plating the dissociated tumor (as described in Step 61d), remove the media from each well. 24 h after plating the dissociated tumor (as described in Step 61d), remove the media from each well. iii.Add 1.5 × 105 BMDMs per well in 1 mL of fresh maintenance media supplemented with 10 ng/mL CSF-1.Note: It is important to use fluorescently labeled BMDMs to be able to distinguish them from the macrophages already present within the dissociated tumor.Alternative: Media from tumor plates can be collected and BMDMs can be exposed to this collected tumor-conditioned media instead of performing a co-culture assay. Add 1.5 × 105 BMDMs per well in 1 mL of fresh maintenance media supplemented with 10 ng/mL CSF-1.Note: It is important to use fluorescently labeled BMDMs to be able to distinguish them from the macrophages already present within the dissociated tumor.Alternative: Media from tumor plates can be collected and BMDMs can be exposed to this collected tumor-conditioned media instead of performing a co-culture assay. Note: It is important to use fluorescently labeled BMDMs to be able to distinguish them from the macrophages already present within the dissociated tumor. Alternative: Media from tumor plates can be collected and BMDMs can be exposed to this collected tumor-conditioned media instead of performing a co-culture assay. iv.Add myelin debris (isolated during Step 59b) to one well of each condition, distributing it equally among the conditions (i.e., if tumor was split into 6 conditions, add 1/6 of collected myelin debris per condition). Add myelin debris (isolated during Step 59b) to one well of each condition, distributing it equally among the conditions (i.e., if tumor was split into 6 conditions, add 1/6 of collected myelin debris per condition). v.Incubate for 48 h at 37°C. Incubate for 48 h at 37°C. vi.Proceed to LLM staining as described in Steps 33 to 39. Proceed to LLM staining as described in Steps 33 to 39. b.To assess proliferation of tumor cells after BMDM co-culture, proceed as follow:i.24 h after plating the dissociated tumor (Step 61d), replace media with low-serum media and add myelin debris to one well of each condition, distributing it equally among the conditions as described above.Optional: Instead of using low-serum media, this assay can be performed with lipid-free medium (see materials and equipment section). Alternatively, both media can be tested if each tumor condition was split into 4 instead of into 2 parts.ii.Incubate for 48 h at 37°C.iii.Perform EdU staining as described in Steps 50 to 58 to assess tumor cell and/or BMDM proliferation. To assess proliferation of tumor cells after BMDM co-culture, proceed as follow:i.24 h after plating the dissociated tumor (Step 61d), replace media with low-serum media and add myelin debris to one well of each condition, distributing it equally among the conditions as described above.Optional: Instead of using low-serum media, this assay can be performed with lipid-free medium (see materials and equipment section). Alternatively, both media can be tested if each tumor condition was split into 4 instead of into 2 parts.ii.Incubate for 48 h at 37°C.iii.Perform EdU staining as described in Steps 50 to 58 to assess tumor cell and/or BMDM proliferation. i.24 h after plating the dissociated tumor (Step 61d), replace media with low-serum media and add myelin debris to one well of each condition, distributing it equally among the conditions as described above.Optional: Instead of using low-serum media, this assay can be performed with lipid-free medium (see materials and equipment section). Alternatively, both media can be tested if each tumor condition was split into 4 instead of into 2 parts. 24 h after plating the dissociated tumor (Step 61d), replace media with low-serum media and add myelin debris to one well of each condition, distributing it equally among the conditions as described above.Optional: Instead of using low-serum media, this assay can be performed with lipid-free medium (see materials and equipment section). Alternatively, both media can be tested if each tumor condition was split into 4 instead of into 2 parts. Optional: Instead of using low-serum media, this assay can be performed with lipid-free medium (see materials and equipment section). Alternatively, both media can be tested if each tumor condition was split into 4 instead of into 2 parts. ii.Incubate for 48 h at 37°C. Incubate for 48 h at 37°C. iii.Perform EdU staining as described in Steps 50 to 58 to assess tumor cell and/or BMDM proliferation. Perform EdU staining as described in Steps 50 to 58 to assess tumor cell and/or BMDM proliferation. Expected outcomes This workflow encompasses methodologies to identify and study lipid-laden macrophages in the context of glioblastoma, as extensively presented in Kloosterman, Erbani and colleagues.1 However, this protocol is also designed to be applicable to different tumor types, and the anticipated outcomes of experiments will be dependent on the tissue used. Alternatives were provided throughout the protocol to guide the reader through experimental adaptations where needed. Additionally, while these protocols were optimized for murine samples, they can be adapted to primary human tissue provided that the flow cytometry panels are adjusted, and that the reagents are compatible with human samples. To illustrate these context-dependent results, we performed transcriptional analyses of LLMs in a hepatocellular carcinoma (HCC) murine model.7 Based on the relative lipid pathway activity patterns of LLMs in HCC samples compared to those in glioblastoma, we observed an increase in cholesterol biosynthesis and lipid uptake pathway, suggesting LLMs in HCC acquire their lipids through a different mechanism (Figure 8A). Based on these results, we hypothesize that macrophages in HCC at least partly acquire a lipid-laden phenotype through de novo cholesterol biosynthesis or receptor-mediated lipid uptake. Potential outcomes and relevant assays to test the scRNA-seq generated hypothesis in multiple tumor types (A) Relative lipid pathway activity in LLMs shows HCC-specific LLMs have less lipid export and phagocytosis activity, whereas general lipid uptake and cholesterol biosynthesis activity is generally higher compared to LLMs in glioblastoma. (B) Depending on the analysis of the scRNA-seq dataset, we suggest the following experiments related to the pathways enriched in the context of specific LLMs. The expected outcomes and proposed methods to validate these hypotheses in any tumor types are summarized in Figure 8B and are further detailed below. TIF analysis The interstitial fluid collected from the tumors, described at Step 2, can be used for a wide range of lipidomics analyses, such as untargeted lipidomic analysis by LC-MS/MS,21 sterol analysis using GC-MS22 or quantitative lipidomics on the Lipidyzer.23 The levels of various lipid classes can be compared to interstitial fluid from healthy tissue, or from tumors of animals treated with any drug of interest (for example, interfering with lipid metabolism and exchange). In combination with the bioinformatic analyses described above, increased levels of specific lipid species found in the TIF can provide an indication of the source of lipids for LLMs, or point towards efflux of lipids by specific cells such as LLMs (and potentially exchanges of lipids within the TME). These hypotheses can be further tested by the functional experiments described below. In vitro lipid uptake assays The in vitro assays described in this protocol have been designed to validate the potential lipid source of LLMs and their ability to transfer these lipids to tumor cells. For example, to test the hypothesis emerging following scRNA-seq analysis of the HCC sample, we suggest performing Steps 29 to 39 to assess whether the lipid content of macrophages can be increased solely by exposure to TCM produced from cell lines generated in Step 8. Adding specific inhibitors for lipid receptors upregulated in HCC-LLMs (based on the scRNA-seq analysis) during these LLM formation assays will elucidate the mechanism underlying the lipid accumulation in HCC-resident macrophages. Alternatively, if the LLM phenotype from macrophages isolated from other organs than the brain relies on enhanced phagocytosis, as seen in glioblastoma, it is likely not based on myelin uptake. Therefore, other lipid-rich structures present within that tissue may be responsible for LLM accumulation. For example, lipid-rich pulmonary surfactant in the lungs24,25 or lipid-rich necrotic cores in breast cancer26 are examples of such local lipid sources. In these cases, it is crucial to purify these sources of lipids and include them in the relevant protocols instead of myelin, to validate their contribution to LLM formation. In vitro lipid transfer assays Click chemistry-based lipid-transfer assays allow precise tracing of lipid classes without interfering with their physico-chemical properties and integration within cellular metabolism.20 In this protocol, we describe tracing of cholesterol with click chemistry, however multiple other lipid species with a click handle are commercially available, such as palmitic, stearic, oleic, palmitoleic, linoleic and arachidonic acids, which allows modification of the experimental setup based on specific hypotheses and scientific questions. Ex vivo functional assays To validate the pro-tumorigenic role of macrophages in tumor cell lipid metabolism, we designed an ex vivo system which closely resembles the in vivo environment, with interchangeable steps to expose the pro-tumorigenic function of LLMs. Importantly, adding pharmacological inhibitors (designed to target potential mechanisms identified in the previous steps of this workflow) to these ex vivo assays allows detailed mechanistic examination of selected processes, such as Valspodar to block ABCA1/ABCG1-mediated cholesterol efflux. Quantification and statistical analysis Flow cytometry data was analyzed with FlowJo version 10.8.0. Prism version 10.0.3 was used to generate graphs. Data is presented as ± SEM. The single cell expression data was loaded, analyzed and visualized in R version 4.1.1 using Seurat v4.4. and SeuratObject v4.0.27 Limitations This protocol was specifically optimized for the study of lipid-laden macrophages in glioblastoma tumor tissue. Applying this workflow to a different tumor type will require to adjust the sorting strategy, and possibly the tissue digestion method to ensure optimal cell viability for ex vivo assays. It is possible that some tumors originating from other tissues do not contain lipid-laden macrophages, and it is therefore crucial to first analyze lipid-laden macrophage content before performing functional assays. Moreover, the code and instructions for bioinformatic analyses described in Steps 17 to 24 of this protocol are designed only to provide an indication of the potential source of lipids driving the LLM phenotype, and thorough mechanistic validation is required to confirm the hypotheses stemming from these computational analyses. Here, we provided examples of such mechanistic validations (Steps 60 to 62) that are applicable for situations where lipid-laden macrophages acquire lipids from an external source of lipids present in the TME (myelin debris in this case). However, if the computational analyses of Step 24 point towards increased biosynthesis activity, rather than an external source of lipids (such as observed in HCC model7), the functional studies should be modified according to the researchers’ hypothesis. Suggestions for adjustments of the experimental setup have been stated throughout this protocol. Troubleshooting Problem 1 At Step 16 the number of LLMs obtained from the sort is too low for downstream analyses. Potential solution Some applications, particularly lipidomic analyses for example, require a high number of LLMs (>3 × 105). It is possible to pool sorted LLMs from multiple biological replicates, as long as the matched non-LLMs from the same biological replicates are similarly pooled. Problem 2 At Step 60, ex vivo cultured tumor cells do not grow. Potential solution Optimize the cell density and well size so that tumor cells are not too sparse, which can impact their growth. Problem 3 Lack of consistency between batches of cell lines generated from the murine tumors (Step 8a). Potential solution To limit batch-to-batch variation between the cell lines, freeze down a large number of vials from a single tumor (>30 vials) at an early passage (p7-p10). Do not keep the cells in culture later than passage 20, and do not freeze down again, as another freeze-thaw may alter the cells’ phenotype. We recommend extensive characterization of each new cell line prior to use in functional assays, to ensure a consistent phenotype. We recommend regular preparation of cell lines from tumors to ensure reliable material for experiments. Problem 4 After the washing steps of Step 41, there are not enough macrophages to perform a lipid transfer experiment. Potential solution Significant loss of macrophages can be expected during the extensive washing performed at Step 41. To anticipate for this loss, the number of macrophages to incubate with the clickable lipids should be approximately 10 times higher than what is needed for the experiment. Problem 5 There are no EdU+ (proliferating) tumor cells in the readout for Step 58. Potential solution Seeding density must be optimized to ensure that the cells do not reach confluency before the end of the experiment, which can lead to cell cycle arrest; conversely, cells seeded too sparsely can also have altered proliferation. Since multiple freeze/thaw cycles of the EdU compound may affect its stability, we recommend preparing small aliquots of the stock solution and thawing each vial only once. Resource availability Lead contact Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Dr. Leila Akkari (l.akkari@nki.nl). Technical contact Further technical information requests should be directed to the technical contact, Daan J. Kloosterman (d.kloosterman@nki.nl). Materials availability No unique reagents were generated in this study. Data and code availability •Data curated or generated for this protocol is originally derived from Kloosterman and Erbani et al.1 and Ramirez, Taranto and Ando-Kuri et al.7 and is available at GSE266149 and GSE216805 respectively. Data curated or generated for this protocol is originally derived from Kloosterman and Erbani et al.1 and Ramirez, Taranto and Ando-Kuri et al.7 and is available at GSE266149 and GSE216805 respectively. •The reference_dataset.rds dataset can be downloaded from the following Zenodo https://doi.org/10.5281/zenodo.13811090. The reference_dataset.rds dataset can be downloaded from the following Zenodo https://doi.org/10.5281/zenodo.13811090. •Any additional information required to reanalyze the data reported in this paper is available upon request from the lead contact. Any additional information required to reanalyze the data reported in this paper is available upon request from the lead contact. Acknowledgments This research was supported by the Dutch Cancer Society (2016-10658, 2018-12049, and 2022-14530 to L.A.), European Research Council (ERC SYN 101118999 to L.A.), Oncode Institute (L.A.), and Dutch Research Council (Vidi 91719355 and ENW-XL21-071 to L.A.). Author contributions D.J.K. and M.F. conceived the methods; D.J.K. performed computational analyses and curated the datasets for this study; D.J.K. and M.F. prepared the figures; J.E. and L.A. provided overall supervision; L.A. acquired funding for this study; and D.J.K., M.F., M.B., J.E., and L.A. wrote and edited the manuscript. Declaration of interests L.A., D.J.K., and J.E. are inventors on European patents P091147NL and P099572EP describing relevant claims. Contributor Information Daan J. Kloosterman, Email: d.kloosterman@nki.nl. Johanna Erbani, Email: j.erbani@nki.nl. Leila Akkari, Email: l.akkari@nki.nl. References Associated Data Data Availability Statement •Data curated or generated for this protocol is originally derived from Kloosterman and Erbani et al.1 and Ramirez, Taranto and Ando-Kuri et al.7 and is available at GSE266149 and GSE216805 respectively. Data curated or generated for this protocol is originally derived from Kloosterman and Erbani et al.1 and Ramirez, Taranto and Ando-Kuri et al.7 and is available at GSE266149 and GSE216805 respectively. •The reference_dataset.rds dataset can be downloaded from the following Zenodo https://doi.org/10.5281/zenodo.13811090. The reference_dataset.rds dataset can be downloaded from the following Zenodo https://doi.org/10.5281/zenodo.13811090. •Any additional information required to reanalyze the data reported in this paper is available upon request from the lead contact. Any additional information required to reanalyze the data reported in this paper is available upon request from the lead contact.